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I. INTRODUCTION

Curiouserand curiouser!'
Every so often a case comes along that is equally interesting for its
non-legal oddities as it is for its legal merits. 2 Associationfor Molecular
Pathology v. U.S. Patentand Trademark Office3 (BRCA Lawsuit) is one
of those cases. The BRCA Lawsuit is significant enough that scholars,
bloggers, pundits, students, scientists, politicians, and many others have
provided comments on the BRCA Lawsuit, ranging from in-depth
analyses to unsubstantiated opinions.4
1. Alice, Alice's Adventures in Wonderland, Lewis Carroll (1865).
2. One example is Markman v. Westview Instruments, Inc., 772 F. Supp. 1535 (E.D. Pa.
1991), where a relatively-unremarkable three-page opinion by Judge Katz spawned a sua sponte
en banc review by the Court of Appeals for the Federal Circuit, resulting in over 60 pages of
sharply-divided opinions, including a majority opinion, two concurring opinions, and a lone
dissenting opinion, eventually leading to appellate review by the Supreme Court of the United
States, resulting in one of the central cases in patent law. See Sam S. Han, Daubert v. Markman:
Fact Experts on Issues that are Wholly Devoid of Any Factual Component, 50 IDEA 367, 37780 (2010).
3. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09-4515-RWS
(S.D.N.Y., filed May 12, 2009).
4. See, e.g., Alex Osterlind, Staking a Claim on the Building Blocks of Life: Human
Genetic Material within the United States Patent System, 75 Mo. L. REv. 617 (2010); Lisa L.
Ouellette, Access to Bio-Knowledge: From Gene Patents to Biomedical Materials, 2010 STAN.
TECH. L. REv. NI (2010); Scott R. Powell & Gerry J. Elman, Getting Beyond the ACLU and
Public Patent Foundations Anti-Gene-Patent Grandstanding, 29 BIOTECHNOLOGY L. REP. 23

(2010); Christopher M. Holman, Learningfrom Litigation: What can Lawsuits Teach Us About
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While many peculiarities can be found in the BRCA Lawsuit, one
noteworthy oddity relates to the affidavits submitted by several of the
individual plaintiffs5 and the plaintiffs' arguments that gene-related
patents are non-statutory subject matter.6 The reason that the plaintiffs'
position is so bizarre is that several of the individual plaintiffs are also
inventors on isolated-sequence-related patents or patent applications.
Thus, on one hand, these plaintiffs submit that Myriad's BRCA
isolated-sequence-related patents are directed to non-statutory subject
matter; yet, on the other hand, they submit that their own isolatedsequence-related patents are directed to patentable subject matter.
This Article asks some very simple questions in view of this
apparent schism. Namely, what happens when an inventor applies for a
patent for an invention that the inventor does not believe to be
patentable, yet withholds that information from the U.S. Patent and
Trademark Office (USPTO or PTO)? Correspondingly, what happens
when the inventor's attorney, or other entity that is substantively
involved in prosecuting the patent, has information that the subject
matter is non-statutory, yet withholds that information from the
USPTO?
We begin this Article by providing background information on the
general entities that are involved in the isolated-sequence-patenting
controversy. Hopefully, this historical context helps the reader
understand why the BRCA Lawsuit is significant. In the background
part, we also discuss specific academic institutions and the general
process by which those institutions apply for patents.
After setting out the background information, we describe our
methodology for determining which issued patents and published patent
applications are relevant to our analysis, and provide the results as they
relate to specific academic institutions.
the Role of Human Gene Patents in Research and Innovation?, 18 KAN. J.L. & PUB. POL'Y 215
(2009); Lauren M. Dunne, "Come, Let us Return to Reason ": Association of Molecular

Pathology v. USPTO, 20 DEPAUL J. ART, TECH. & INTELL. PROP. L. 473 (2010); Jennifer
Giordano-Coltart et al., No Legal Monopoly for Genes: Court Rules Genes are Unpatentable
Subject Matter, 22 INTELL. PROP. & TECH. L.J. 8 (2010); Debra Greenfield, Intangible or
EmbodiedInformation: the Non-StatutoryNature ofHuman Genetic Material,25 SANTA CLARA
COMPUTER & HIGH TECH. L.J. 467 (2009).

5. Ass'n for Molecular Pathology, No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009),
Doc. Nos. 40 (Declaration of Wendy K. Chung (Columbia)), 47 (Declaration of Harry Ostrer
(NYU)), 48 (Declaration of David H. Ledbetter (Emory)), 78 (Chung), 85 (Ostrer) & 86
(Ledbetter).
6. Id. Doc. Nos. 61 & 62 (Plaintiffs' Motion for Summary Judgment and Memorandum
in Support of Motion).
7. The phrases "statutory subject matter" and "patentable subject matter" are used
interchangeably in this Article.
8. Ass'n for Molecular Pathology,No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009),
Doc. No. 1, Complaint.
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Once our methodology and results are tallied, we next discuss the
cases that are central to our Article. First, we review the relevant
portions of the proceedings, focusing particularly on several individual
plaintiffs, their positions in the BRCA Lawsuit, and sworn statements
filed by those plaintiffs in the BRCA Lawsuit. Second, we discuss the
law relating to inequitable conduct, specifically reviewing the highly
divided en banc opinion in Therasense v. Becton, Dickinson & Co.9
This review of inequitable conduct provides the legal context in which
we examine the plaintiffs' statements. Thereafter, we analyze the
isolated-sequence-related patent portfolios of the relevant institutions to
determine the extent to which the isolated-sequence-related patents are
susceptible to allegations of inequitable conduct.

II. BACKGROUND
All the world's a stage,And all the men and women
merely players ... .0
We begin our Article with some background information on the
players and events relevant to the BRCA Lawsuit. This background
information provides context to understanding the historical
significance of the BRCA Lawsuit. We begin with the relevant entities
and then move to events.
A. The Players
Because the Complaint contains the named plaintiffs and defendants,
this part only recites relevant entities that are not parties to the BRCA
Lawsuit.II
1. James D. Watson
James Dewey Watson, Ph.D., along with his counterpart Francis H.
C. Crick,12 is a household name in biology, chemistry, genetics, and
even history. Dr. Watson is most famous for his Nobel-prize-winning

9. Therasense, Inc. v. Becton, Dickinson & Co., Slip Opinion, Consolidated Case
Numbers 2008-1511, -1512, -1513, -1514, -1595 (Fed. Cir., decided May 25, 2011).
10. Jaques, As You Like It, Act 11, scene vii, William Shakespeare (1623).
11. When appropriate, any information on the parties themselves, which is unavailable
from the court documents, is provided within the substantive text of this Article, infra.
12. The Nobel Prize in Physiology or Medicine 1962, Biography, NOBELPRIZE.ORG,
http://nobelprize.org/nobelprizes/medicine/laureates/1962/crick-bio.html (last visited Sept. 13,
2011) (providing a biography of Francis Harry Compton Crick).
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discovery of the double-helical structure of nucleic acids.13 The
Watson-Crick double-helical structure of deoxyribonucleic acid (DNA)
forms one of the foundational building blocks' 4 of genetic research.
Relevant to this Article, Dr. Watson's significance derives from his role
at the National Institutes of Health (NIH) between 1990 and 1992,
where he headed the Human Genome Project.' 5 This project now falls
under the National Human Genome Research Institute (NHGRI).16
Being no stranger to controversy, Dr. Watson recently announced his
"decision to retire" after stating that black people are less intelligent
than other persons. Dr. Watson had already made similar statements
about women.' 8 In the context of the BRCA Lawsuit, Dr. Watson took a
position against patenting of genes, indicating that such a decision was
"sheer lunacy."'
2. Bernadine Healy
We next describe Bernadine Healy, M.D. Though Dr. Healy most
recently worked as the Health Editor for U.S. News & World Report,2 0
her significance with reference to the BRCA Lawsuit traces back to her
21
role as the first female director of the NIH, immediately after serving
as the director of the Cleveland Clinic in Ohio. 22
Insofar as the NHGRI is the genomic research division of the NIH,
the organizational structure places the head of the NHGRI (e.g., Dr.
13. Nobelprize.org, The Nobel Prize in Physiology or Medicine 1962, Francis Crick,
James Watson, Maurice Wilkins, at http://www.nobelprize.org/nobel prizes/medicine/laureate
s/1962/.
14. No pun intended.
15. James D. Watson, Wikipedia.org, http://en.wikipedia.org/wiki/JamesD._Watson (last
visited Sept. 13, 2011); Former NHGRI Directors, James D. Watson, NATIONAL HUMAN
GENOME RESEARCH INSTITUTE, http://www.genome.gov/27528266#al-4 (last updated May 8,

2011).
16. For simplicity, we refer to both the predecessor entity (National Center for Human
Genome Research (NCHGR)) and the current entity as the NHGRI, because for purposes of this
Article there is no distinction between the NCHGR and the NHGRI.
.17. Helen Nugent, Black People 'Less Intelligent' Scientist Claims, TIMES (Oct. 17,
2007), http://www.timesonline.co.uk/tol/news/uk/article2677098.ece; Statement by Francis S.
Collins, MD.,

Ph.D.,

Director, NATIONAL

HUMAN

GENOME

RESEARCH

INSTITUTE,

http://www.genome.gov/26023457 (last updated Apr. 28, 2011).
18. Nugent, supra note 17.
19. Philip J. Hilts, Head of Gene Map Threatens to Quit, N.Y. TIMES (Apr. 9, 1992),
http://www.nytimes.com/1992/04/09/us/head-of-gene-map-tbreatens-to-quit.html.
20. Healy, Bernadine, MD., U.S. News and World Report, http://www.usnews.com/
topics/author/bernadinehealy (last visited Sept. 13, 2011).
21. Changing the Face of Medicine: Bernadine Healy, Ph.D, NATIONAL LIBRARY OF

MEDICINE [hereinafter Changing the Face of Medicine], http://www.nlm.nih.gov/changingthe
faceofmedicine/physicians/biography 145.htm (last visited Sept. 13, 2011).
22. Id.
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Watson) below the director of the NIH (e.g., Dr. Healy).23 Knowing
how Dr. Watson feels about women in science, it should come as no
surprise that there was an underlying tension between Dr. Watson and
Dr. Healy, because Dr. Healy was at that time Dr. Watson's boss. 2 4
Compounding to this tension, Dr. Healy took the position that genes
should be patentable,2 5 and, under her direction, the NIH applied for
several patents on gene fragments, known as expressed sequence tags
(EST).2
3. John Craig Venter
This next brings us to John Craig Venter, Ph.D., a former NIH
scientist 27 who is also an entrepreneurial biologist and the founder of
Celera Genomics (Celera),2 8 The Institute for Genomic Research
(TIGR) 29 and J. Craig Venter Institute (JCVI). 30 Dr. Venter is largely
credited with leading the private-sector push to sequence the human
genome. 3 1
Unlike many other genetic scientists, Dr. Venter was not concerned
with finding every human gene, but rather concerned with the fastest
possible route to discovering a useful catalog of most human genes.32
Being in the private sector, and seeking a participant who sought to
quickly discover the most number of useful genes, it should come as no
surprise that Dr. Venter is a strong proponent of patenting genes. 33
Indeed, the USPTO has issued 14 patents on protein sequences between
Celera and JCVI. 34
23.

Management OrganizationalChart,NATIONAL INSTITUTES OF HEALTH, http://oma.od.

nih.gov/manualchapters/management/1 123/nih.pdf.
24. Id.
25. Jeremy Cherfas, Change of Emphasis on Genome Project, 304 BRIT. MED. J. 1132-33
(1992).
26. Craig Venter, WIKIPEDIA.ORG, http://en.wikipedia.org/wiki/CraigVenter (last visited
Sept. 13, 2011).
27. Id.
28. For more information on Celera Genomics, see its website at https://www.celera.com.
29. The Institute for Genomic Research, WIKIPEDIA.ORG, http://en.wikipedia.org/wikil
TheInstitute for GenomicResearch (last visited Sept. 13, 2011).
30. For more information on the J. Craig Ventor Institute, see its website at
http://wwwjcvi.org.
31. Unique DNA Database Has Helped Advance Scientific Discoveries Worldwide, NIH
MEDICINE PLUS, Spring 2008, at 26-27, available at http://www.nlm.nih.gov/medlineplus/
magazine/issues/spring08/articles/spring08pg26-27.html.
32. Paul M. Rowe, Patenting Genes: J. Craig Venter and the Human Genome Project, 1
MOL. MED. TODAY 12-14 (1995).

33. Id.
34. USPTO search result for AN/(Celera OR "Craig Venter"), http://patft.uspto.gov/neta
cgi/nph-Parser?Sectl=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.Htm
&r-0&f='S&1=50&d=PTXT&RS=AN%2F%28celera+OR+%22craig+venter/o22%29&Refine
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Dr. Venter's significance to the BRCA Lawsuit derives from his
tension with Dr. Watson, insofar as Dr. Venter was one of the first
applicants for gene-related patents from the NIH.35 At the time that Dr.
Venter's team filed for patent protection on protein structures, Dr.
Watson was Dr. Venter's boss.
4. Francis Sellers Collins
Next on our list is Francis S. Collins, M.D., Ph.D.,3 6 who is credited
with spearheading (while he was the director of the NHGRI) the efforts
to map the entire human genome. 37 Dr. Collins was recently nominated
by President Obama, and unanimously confirmed as the head of the
NIH. 3 8 Though Dr. Collins engages in hearty debates on science and
morality,3 9 he has indicated that patenting genes is more of a legal issue
than it is of a moral issue.40
Given Dr. Collins's seeming ambivalence on gene patents, one may
wonder why Dr. Collins is relevant to this Article. First, and wholly
irrelevant to this Article, is the author's proclivity for gratuitously
mentioning the University of Michigan at every opportunity. 4 ' Dr.
Collins, who comes to the NIH from Michigan,4 2 stands in contrast to
Dr. Healy, who came to the NIH from Ohio.4 3 For those familiar with
the Michigan-Ohio State arch-rivalry," this is in and of itself, very
interesting. The fact that Drs. Healy and Collins worked well together
and still have the utmost respect for each other,45 is evidence of how
=Refine+Search&Refine=Refine+Search&Query-an%2F%28celera+OR+%22craig+venter/o22
%29.
35. Craig Venter, supra note 26.
36. The NIH Director, NATIONAL INSTITUTES OF HEALTH, http://www.nih.gov/about/

director/ (last visited Sept. 13, 2011).
37. Leon Rosenburg, Introductory Speech for FrancisS. Collins, AM. J. HUM. GENETICS,
(Oct. 28, 2005), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 1559551/.
38. Biographical Sketch of Francis S. Collins, MD., Ph.D., NATIONAL INSTITUTES OF

HEALTH, http://www.nih.gov/about/director/directorbio.htm (last visited Sept. 13, 2011).
39. Dan Cray, God v. Science, TIME MAG. (Nov. 5, 2006), http://www.time.com/time/ma
gazine/article/0,9171,1555132,00.html.
40. Francis Collins, PBS.ORG, http://www.pbs.org/faithandreason/transcript/coll-frame.
html (last visited Sept. 13, 2011).
41. In the spirit of full disclosure, Dr. Collins's very lovely daughter was a high-school
classmate of the author. She went on to pursue the noble profession of becoming a medical
doctor, while the author became an attomey. Insofar as the author's high-school-related drama is
irrelevant to this Article, we will not engage in any further discussion of those topics.
42. BiographicalSketch of FrancisS. Collins, MD., Ph.D., supra note 38.
43. Changing the Faceof Medicine, supra note 21.
44. The 10 Greatest Rivalries, ESPN.coM (Jan. 3, 2007), http://espn.go.com/endof
century/s/other/bestrivalries.html.
45. Bernadine Healy, M.D., Francis Collins: Leader for the 21st Century NIH,
HEALTHUSNEWS.COM (July 9, 2009), http://health.usnews.com/health-news/blogs/heart-to-
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science can transcend boundaries.
Second, and more relevant to this Article, Dr. Collins discovered the
procedure for positional cloning, 46 a groundbreaking method that
Some opine that this
allowed quicker discovery of genes.
revolutionary method of transcribing genes, in conjunction with the race
between the pro-patent and anti-patent scientists, contributed to the
entire human genome being mapped well ahead of schedule.4 8
5. The University of Pennsylvania
For reasons that will become apparent later, we now divert our
attention from the NIH and focus on the University of Pennsylvania and
its affiliates. Of particular relevance to this Article are the Trustees of
the University of Pennsylvania, 49 the University of Pennsylvania School
of Medicine,o and the Hospital of the University of Pennsylvania.5
None of these entities are parties to the BRCA Lawsuit. However, the
University of Pennsylvania School of Medicine5 2 and the Hospital of
the University of Pennsylvania, 53 employ Drs. Haig Kazazian and
Arupa Ganguly, respectively. These are two of the named Plaintiffs.
The University of Pennsylvania became formally incorporated in
1791 and currently exists, under the name Trustees of the University of
Pennsylvania, as a private, non-profit, educational corporation.5 4 The
Trustees of the University of Pennsylvania currently own all of the
intellectual property for the University of Pennsylvania, including all
technical information, trade secrets, developments, discoveries,
inventions, know-how, methods, techniques, formulae, data, processes,

heart/2009/07/09/francis-collins-leader-for-the-21 st-century-nih.
46. Francis S. Collins & Sherman M. Weissman, DirectionalCloning ofDNA Fragments
at a Large Distancefrom an Initial Probe: A CircularizationMethod, 81 PROC. NAT'L ACAD.
SCI. USA 6812-16 (1984).

47. Jill Adams, Sequencing Human Genome: The Contributions of Francis Collins and
Craig Venter, I NATURE EDUC. (2008).

48. Id.
49. Board of Trustees, UNIV. OF PA., https://secure.www.upenn.edu/secretary/trustees/
index.html (last visited Sept. 13, 2011).
50. The University of Pennsylvania School of Medicine, UNIV. OF PA., http://www.med.
upenn.edu/ (last visited Sept. 13, 2011). See also University of Pennsylvania School of
Medicine, WIKIPEDIA.ORG, http://en.wikipedia.org/wiki/University of Pennsylvania School of
Medicine (last visited Sept. 13, 2011).
51. The Hospital of the University of Pennsylvania, http://www.pennmedicine.org/hup/;
see also Hospital of the University of Pennsylvania, wikipedia.org, http://en.wikipedia.org/
wiki/Hospital of the University of Pennsylvania
52. BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009), Complaint 11.
53. Id. Complaint 12.
54. Pennsylvania Department of State, http://www.corporations.state.pa.us.
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and other proprietary ideas and matters.5 5
In 2003, the Trustees of the University of Pennsylvania reserved,
along with the Pennsylvania Department of State, the fictitious names
"The Hospital at University of Pennsylvania School of Medicine" and
the "University of Pennsylvania Medical Center." 56 Eventually, in 2008,
the University of Pennsylvania School of Medicine became
incorporated as Penn Medicine.57 Both the Hospital at the University of
Pennsylvania and the University of Pennsylvania School of Medicine
are part of Penn Medicine, and the Trustees of the University of
Pennsylvania 58 currently own both. 59
The University of Pennsylvania applies for patent protection through
60
its Center for Technology Transfer (UPenn-CTT). Once an invention
is received by UPenn-CCT, an assigned Technology Licensing Officer
(TLO) works with the inventor, recommends an intellectual-propertyprotection strategy, and assesses the invention's commercial value. 6 1 if
TLO determines that an invention potentially has commercial value,
UPenn-CCT files for patent protection. The filing occurs at UPennCCT's own expense and in the name of the University of
Pennsylvania. 62
Regarding the life sciences, the relevant UPenn-CCT TLOs6 3
include: Michael J. Cleare, Ph.D.;64 John S. Swartley, Ph.D.; 65 Shilpa
55. Patent and Tangible Research Property Policies and Procedures of the University of
Pennsylvania, Almanac supp., July 13, 2010.
56. Pennsylvania Department of State, supra note 54.
57. Id.
58. Id.
59. Id.
60. Center For Technology Transfer, UNIVERSITY OF PENNSYLVANIA, http://www.ctt.
upenn.edulindex.html (last visited Aug. 15, 2011); About CITT CENTER FOR TECHNOLOGY
TRANSFER, UNIVERSITY OF PENNSYLVANIA, http://www.ctt.upenn.edu/whoweare.html (last

visited Aug. 15, 2011).
61.

Process, CENTER FOR TECHNOLOGY TRANSFER, UNIVERSITY OF PENNSYLVANIA, http://

www.ctt.upenn.edu/techtransfer.html (last visited Aug. 15, 2011); After Disclosure,CENTER FOR
TECHNOLOGY

TRANSFER,

UNIVERSITY

OF

PENNSYLVANIA,

http://www.ctt.upenn.edulafter

disclosure.html (last visited Aug. 15, 2011).
62. Process,supra note 61; After Disclosure,supra note 61.
63. Although there may be other individuals at UPenn-CCT that are involved in the filing
and prosecution of patent applications, for purposes of this Article, we limit the names to
individuals who are: (a) in the life-sciences or medicine; and (b) likely to be substantively
involved in prosecution. Thus, while there are other TLOs in UPenn-CCT, we intentionally
truncate the list to those who seem most relevant in the context of BRCA Lawsuit. Similarly, for
other institutions, we truncate the list to those that are substantively involved in the relevant
field. It should be noted that the TLO personnel may change over time.
64. Associate Vice Provost for Research and Executive Director. Dr. Cleare leads the
outreach to faculty, as well as collaborations with industry and the investment community on a
local, regional and national basis. Who We Are, CENTER FOR TECHNOLOGY TRANSFER,
UNIVERSITY OF PENNSYLVANIA, http://www.ctt.upenn.edulwhoweare.html (last visited Aug. 15,
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Bhansali, Ph.D.;66 James W. Bowen, Ph.D.;67 Man Liang, Ph.D.; 68
Lauren Miller, Ph.D.; 69 Robert H. Schenkel, Ph.D.;70 Heather A.
Steinman, Ph.D.;71 Pamela Beatrice, Ph.D.; 72 Thomas P. Fitzsimons; 73
Jennifer Langenberger; 74 and Michelle McSorley. 75
6. Columbia University
Similar to the University of Pennsylvania, Columbia University is
not a named plaintiff in the BRCA Lawsuit. However, Dr. Wendy
Chung, who is a named plaintiff in the BRCA Lawsuit, is an Associate
Professor of Pediatrics at Columbia University. 7 Dr. Chung filed an
affidavit in the BRCA Lawsuit specifically stating, as a factual matter,
that "[g]enes are products of nature and not inventions of man."77
Columbia University is an independent, privately supported,
nonsectarian institution of higher education whose official corporate
name is "The Trustees of Columbia University in the City of New

2011).
65. Deputy Executive Director. Dr. Swartley leads technology licensing efforts and the
formation of new ventures from UPenn discoveries and faculty expertise. Id.
66. Associate Director. Dr. Bhansali supports the commercialization of technologies in the
physical sciences, primarily from the Department of Chemistry, Chemical Engineering and
Bioengineering. She is also part of the Nanotechnology Commercialization Group of the
Nanotechnology Institute. Id.
67. Assistant Director. Dr. Bowen supports commercialization of technologies efforts for
the life sciences group, primarily from the Department of Medicine. Id.
68. Licensing Officer. Dr. Liang supports commercialization of technologies efforts for
the life sciences group. Id.
69. Associate Director. Dr. Miller is responsible for the management and
commercialization of technologies in the life sciences group. Id.
70. Director. Dr. Schenkel leads the life sciences licensing, whose responsibilities include:
reviewing invention disclosures, supporting the patent protection process, as well as marketing
and licensing of all life sciences technologies. Id.
71. Senior Associate Director. Dr. Steinman is responsible for the management and
commercialization of technologies in the Pathology Department as well as life sciences,
primarily from the Medical School and Dental School. Id.
72. Associate Director. Dr. Beatrice is primarily responsible for the management and
commercialization of technologies in the physical sciences, primarily from the Laboratory for
Research on the Structure of Matter. Id.
73. Director. Mr. Fitzsimons leads the physical sciences licensing team, whose
responsibilities include: reviewing invention disclosures, supporting the patent protection
process, as well as marketing and licensing of all physical sciences technologies. Id.
74. Director Langenberger oversees all components of IP protection, including
management of invention disclosure review, patent filing, prosecution and maintenance. Id.
75. Assistant Director McSorley manages invention disclosure, review, patent filing,
prosecution, and maintenance as well as return to inventor requests. Id.
76. BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12,2009), Complaint % 13.
77. Id. Doc. Nos. 40 & 78 25.

JOURNAL OF TECHNOLOGYLAW & POLICY

12

[Vol. 17

York."78 As such, all patents and other intellectual property rights are
held in the name of the Trustees of Columbia University in the City of
New York.79
Columbia Technology Ventures, 80 through its TLOs, undertakes the
filing and prosecuting of patent applications for Columbia University.
The TLOs coordinate all aspects of evaluating, patenting, marketing,
and licensing any given invention.8 1 The relevant individuals within
Columbia Technology Ventures, who may be substantively involved in
the filing and prosecution of patent applications, include: Orin
Herskowitz;82 Daniel Abraham;8 3 Scot Hamilton;84 David Lemer;8 5
Steve Trost; 86 Ofra Weinberger; 7 Peter Golikov;8 8 Sara Gusik 89 JUllian
Jones; 90 Ron Katz; 9 1 Beth Kauderer; 92 Jerry Kokoshka; 93 Cynthia
Lang; 94 and Donna See. 95
7. Yale University
Founded in 170196 and incorporated in Connecticut in 1887,97 Yale
78. Organization and Governance of the University, COLUMBIA POLICIES, COLUMBIA

UNIVERSITY, http://www.columbia.edu/cu/vpaa/handbook/organization.html (last visited Aug.
16,2011).
79. Appendix D - Statement ofPolicy on ProprietaryRights in the Intellectual Productsof
Faculty Activity, COLUMBIA POLICIES, COLUMBIA UNIVERSITY, http://www.columbia.edu/cu/vp

aa/handbook/appendixd.html (last visited Aug. 16, 2011).
80.

Working with

Tech

Ventures, COLUMBIA TECHNOLOGY VENTURES,

COLUMBIA

UNIVERSITY, http://techventures.columbia.edu/inventors/working-with-techventures (last visited
Aug. 16, 2011).
81. Id.; Submit an Invention, COLUMBIA TECHNOLOGY VENTURES, COLUMBIA UNIVERSITY,

http://techventures.columbia.edulinventors/submit-an-invention (last visited Aug. 16, 2011).
82. Executive Director and Vice President of Intellectual Property & Tech Transfer,
Management, COLUMBIA TECHNOLOGY VENTURES, COLUMBIA UNIVERSITY, http://techventures.

columbia.edu/about/team/management (last visited Aug. 16,2011).
83. Director, Morningside and Lamont-Doherty. Id.
84. Executive Director and Vice President of Intellectual Property & Tech Transfer. Id.
85. Director, Venture Lab. Id.
86. Senior Advisor. Id.
87. Director, Health Sciences. Id.
88. Licensing Officers, COLUMBIA TECHNOLOGY VENTURES, COLUMBIA UNIVERSITY,

http://techventures.columbia.edu/about/team/licensingteam (last visited Aug. 16, 2011).
89. Id.
90. Id.
91. Id.
92. Id.
93. Id.
94. Id.
95. Id.
96. About Yale, HISTORY, YALE UNIVERSITY, http://www.yale.edu/about/history.html (last

visited Aug. 16, 2011).
97. Commercial Recording Division, SECRETARY OF THE STATE OF CONNECTICUT,
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University is the third-oldest institution of higher education in the
United States and a private Ivy League university. 98 Within Yale
University's organizational structure resides the Yale School of
Medicine,9 9 which includes the Yale Medical Group,'oo which further
includes the Yale Cancer Genetic Counseling Program.' 0 Although
Yale University is not a party to the BRCA Lawsuit, Ellen Matloff who
is the Director of Yale Cancer Genetic Counseling Program,to is a
named plaintiff in the BRCA Lawsuit.103
All of the patents by Yale University employees are generally owned
by Yale University.'04 Yale University's Office of Cooperative
Research (Yale-OCR) plays a central role in filing and prosecuting all
patent applications for Yale University.' 05 Part of Yale-OCR policies
and guidelines includes a publication on the Rule 56 duty of candor and
good faith as required by the USPTO.106 As such, there is little doubt
that the individuals in the Yale-OCR, who are substantively involved in
filing and prosecuting patent applications, are aware of their duties to
disclose relevant information to the USPTO. The individuals in the
Yale-OCR who are responsible for patent filing and prosecution
include: Jon Soderstrom; 07 John W. Puziss; 08 David A. Lewin;109
Hong Peng;o Christopher Unsworth;"' and Diane K. Harmon.11
http://www.concord-sots.ct.gov/CONCORD/index jsp (last visited Aug. 16, 2011).

98. Yale University, WIKIPEDIA.ORG, http://en.wikipedia.org/wiki/YaleUniversity (last
visited Aug. 16, 2011).
99. Yale School of Medicine, WIKIPEDIA.ORG, http://en.wikipedia.org/wiki/Yale School_
of Medicine (last visited Sept. 23, 2011).
100. Yale Medical Group, YALE-NEw HAVEN HOSPITAL, http://www.ynhh.org/health-pro
fessionals/yale medicalgroup.aspx (last visited Sept. 23, 2011).
101. Genetic Counseling Program, YALE CANCER CENTER, http://medicine.yale.edu/can
cer/patient/support/genetics/index.aspx (last visited Sept. 23, 2011).
102. Ellen T. Matloff C.G.C.,

YALE MEDICAL GROUP, YALE SCHOOL OF MEDICINE,

http://www.yalemedicalgroup.org/YMG/directory/public/profile.asp?pictid-63322&department
=PB941646&physicianList-109787 (last visited Aug. 16, 2011).
103. BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009), Complaint 17.
104. Yale University PatentPolicy, OFFICE OF COOPERATIVE RESEARCH, YALE UNIVERSITY,

http://www.yale.edu/ocr/pfg/policies/patents.html (last visited Aug. 16, 2011).
105. Patenting, Tech Transfer Process (FAQ), OFFICE OF COOPERATIVE RESEARCH, YALE

UNIVERSITY, http://www.yale.edulocr/about/faq.html#patenting (last visited Aug. 16, 2011).
106. Patent Law You Can Use?,Rule 56 - Duty of Candor and Good Faith, OFFICE OF
COOPERATIVE RESEARCH, YALE UNIVERSITY, http://yale.edu/ocr/pfg/guidelines/patent/rule56.
html (last visited Aug. 16, 2011).
107. Managing Director, Office of Cooperative Research. Who We Are, OCR Team, OFFICE
OF COOPERATIVE RESEARCH, YALE UNIVERSITY, http://www.yale.edulocr/about/who/index.html

(last visited Aug. 16, 2011).
108. Director of Licensing, Office of Cooperative Research. Id.
109. Senior Associate Director, Medical Campus, Office of Cooperative Research. Id.
110.
111.

Associate Director, Medical Campus, Office of Cooperative Research. Id.
Associate Director, Medical Campus. Id.
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8. New York University
Founded in 1841 as the University Medical College, New York
University School of Medicine (NYU-Med) is one of the graduate
schools of New York University (NYU). 13 Currently, the School of
Medicine is part of NYU Langone Medical Center.11 4 Although neither
NYU nor NYU-Med are parties to the BRCA Lawsuit, at least two
plaintiffs employed by NYU are named plaintiffs in the BRCA
Lawsuit."5 Specifically, Dr. Harry Ostrer has filed an affidavit in the
BRCA Lawsuit, specifically stating that "[g]enes are products of nature
and not inventions of man."" 6
NYU's Statement of Policy on Patents provides that any invention
developed at NYU or resulting from research conducted under NYU
auspices must be disclosed and assigned to NYU."' Similar to
processes at other institutions, NYU's Technology Transfer Office
the
Office
of Industrial
officially
called
("NYU-TTO";
Liaison/Technology Transfer) handles the filing and prosecuting of
patent applications.
Once the NYU-TTO receives an invention
disclosure, NYU-TTO personnel determine the invention's potential
commercial viability and decide whether to seek patent protection on
the invention.'1 9 Should the NYU-TTO decide to seek patent protection,
then NYU-TTO personnel coordinate the patent prosecution, relying on
the inventor's participation and a patent attorney's services.
The
Goldfinger;121
Abram
include:
at
NYU-TTO
relevant personnel
Sadhana Chitale, Ph.D.;122 and Prajakta Sonalker, Ph.D.123

112. Director of Intellectual Property Administration. Id.
113. New York University School of Medicine, WIKIPEDIA.ORG, http://en.wikipedia.org/
wiki/NYUSchool of Medicine (last visited Aug. 17, 2011).
114. Id.
115. Dr. Harry Ostrer (Professor of Pediatrics, Pathology, and Medicine; Director, Human
Genetics Program, Department of Pediatrics, NYU-Med) and Prof. Elsa Reich (Professor in the
Department of Pediatrics, NYU); BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12,
2009), Complaint
14 & 18.
116. Id. Doc. Nos. 47 & 85 15.
117. FAQs from the Inventor's Handbook, NYU LANGONE MEDICAL CENTER,
http://oil.med.nyu.edulfaqs-inventors-handbook (last visited Aug. 17, 2011).
118. Id.
119. Id.
120. Id.
121. Executive Director, Industrial Liaison/Technology Transfer. Contact Us, NYU
LANGONE MEDICAL CENTER, http://oil.med.nyu.edu/contact-us (last visited Aug. 17, 2011).

122. Associate Director, Technology Transfer/Life Sciences. Id.
123. Intellectual Property Manager. Id.
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9. Emory University
Incorporated in 1915 as a nonprofit corporation,124 Emory Universit
contains nine academic divisions, including the School of Medicine
Although neither Emory University nor its School of Medicine are
plaintiffs in the BRCA Lawsuit, two professors of Human Genetics,
employed by Emory University, filed affidavits.126 Specifically, Dr.
David Ledbetter's affidavit states that "[g]enes are products of nature
and not inventions of man."1 27
Emory University's Office of Technology Transfer (Emory-OTT)
spearheads all efforts to obtain patents for the University.128 In
particular, Emory-OTT is charged with protecting Emory University's
intellectual property and administering the protection process, such as
filing and prosecuting patent applications. 12 The relevant personnel at
Emory-OTT includes: Todd Sherer, Ph.D.;130 Linda Kesselring,
M.B.A.;13 1 Susanne Hollinger, Ph.D., J.D.;132 Kevin Lei, M.S.,
M.B.A 3 3 J. Cale Lennon, III, Ph.D., M.B.A.;1 34 Chris Paschall,
Ph.D.; 13 Cory Acuff, Ph.D.; 136 Panya Taysavang, M.B.A.;' 3 7 Cliff
Michaels, Ph.D.;38 Randi Isaacs, J.D.;'3 9 and James Mason, M.S.,

J.D. 140
124. Corporations, GEORGIA SECRETARY OF STATE, http://corp.sos.state.ga.us/corp/soskb/
Corp.asp?497845 (last visited Aug. 17, 2011).
125. Emory University, WIKlPEDIA.ORG, http://en.wikipedia.org/wikilEmory University
(last visited Aug. 17, 2001).
126. David Ledbetter, Ph.D. (Professor, Human Genetics, Emory University School of
Medicine; Director, Division of Medical Genetics, Emory University School of Medicine) and
Stephen T. Warren, Ph.D. (Professor, Human Genetics, Emory University; Chair, Department of
Human Genetics, Emory University; Professor, Biochemistry, Emory University; Professor,
Pediatrics, Emory University); BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12,
2009), Complaint T 15-16.
127. Id. Doc. Nos. 48 & 86 $ 27.
128. About Us, OFFICE OF TECHNOLOGY TRANSFER, EMORY UNIVERSITY, http://www.ott.

emory.edu/Office/AboutUs/index.cfm (last visited Aug. 17, 2011).
129. Id.
130. Associate Vice President for Research and Director. Meet the Staff OFFICE OF
TECHNOLOGY TRANSFER, EMORY UNIVERSITY, http://www.ott.emory.edu/Office/AboutUs/ind
ex staff.cfm (last visited Aug. 17, 2011).
131. Director of Operations. Id.
132. Associate Director and Chief Intellectual Property Officer. Id.
133. Associate Director and Venture Lab Director. Id.

134. Assistant Director. Id.
135. Licensing Associate. Id.
136.
137.

Senior Licensing Associate. Id.
Licensing Associate. Id.

138. Id.
139. Patent Counsel. Id.

140. Id.
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B. The BackgroundEvents
With the players now introduced, we now turn our attention to
several events that show how the controversy of patenting human genes
emerged in the scientific community prior to emerging in the context of
the BRCA Lawsuit. Insofar as other authors have described the debate
from a legal perspective,141 we focus on the drama within the scientific
community.
1. Drama at the National Institutes of Health and the First Patent
Applications on Human Genes
In 1984, the National Institutes of Health (NIH) recruited an
enterprising and entrepreneurial individual by the name of J. Craig
Venter for its National Institute of Neurological Diseases and Stroke
(NINDS). 142 Eventually, Dr. Venter became one of the scientists that
would work on the Human Genome Project.143
By 1988, the NIH realized that it needed a genetics research
division. Thus, after much discussion with scientists, administrators,
and policy experts, the NIH established the National Center for Human
Genome Research (NCHGR) in October 1989,144 naming as its first
director the Nobel-prize winning scientist, Dr. James D. Watson.145 By
April 1990, the NCHGR had formulated and published its five-year plan
to map the entire human genome.14 6 Under Dr. Watson's leadership, the
Human Genome Project officially began in October of the same year.147
During this same period, Dr. Venter discovered a new technique for
finding genes by using expressed sequence tags (EST).148 Having an
entrepreneurial spirit, Dr. Venter voiced an interest in patenting these
gene sequences.
Just six months after the official kick-off of the Human Genome
Project, in April 1991, President Bush appointed Dr. Bernadine Healy
141. See, e.g., Andrew Chin, Research in the Shadow of DNA Patents, 7 J. PAT. &
TRADEMARK OFF. Soc'Y 846, 854-78 (2005).

142. Biography 39: John Craig Venter (1946 -), Cold Spring Harbor Laboratory's DNA
Learning Center, http://www.dnalc.org/view/16830-Biography-39-John-Craig-Venter-1946.html (last visited Sept. 14, 2011).
143. Jocelyn Selim & David Ewing Duncan, Discovery Dialogue: Geneticist Craig Ventor,
DISCOVER MAG., Dec. 2004, http://discovermagazine.com/2004/dec/discover-dialogue.
144. About NHGRI: A Brief History and Timeline, NATIONAL HUMAN GENOME RESEARCH

INSTITUTE, http://www.genome.gov/10001763 (last visited Sept. 14, 2011).
145. Id.
146. Id.
147. Id.
148. Biography 39: John Craig Venter (1946 -), supra note 142.
149. Memorandum from Jack Spiegel to Lawrence Goffney (Mar. 21, 1997), available at
http://www.ott.nih.gov/policy/OTTltr21Mar97.pdf.
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as the head of the NIH. so Given Dr. Watson's position on women in
science,' 5 ' one can imagine the tension that arose from Dr. Healy being
appointed as Dr. Watson's boss, especially so soon after the start of the
Human Genome Project.
This tension escalated in June 1991 when Dr. Venter requested the
NIH to file for patent protection on the ESTs.152 Opposing such a
measure, Dr. Watson indicated that patenting human gene sequences
would be "sheer lunacy." 5 3 Over these vehement objections, Dr. Healy
approved the patent applications for Dr. Venter's ESTs, and in June
1991 the NIH and Dr. Venter applied for 2 patents covering 27 15
genes.1 54 This decision resulted in Dr. Watson resigning from his post at
the NCHGR. 5
As a result of public outcry, and in an ironic twist, the NIH withdrew
its human-gene-related patent applications. 156 Unsurprisingly, the
tension between the brightest scientific minds in this field would be a
harbinger of the tension that would eventually arise in the BRCA
Lawsuit.
2. The Rush to Patent
Also, at the NIH, Dr. Watson had rejected Dr. Venter's ideas for
speeding up the sequencing of the human genome. 5 7 Seeing the
commercial possibilities, Dr. Venter resigned from the NIH and sought
private-sector funding for his company, Celera Genomics. 5 8 Insofar as
Dr. Venter had publicly voiced his position on patenting isolated
sequences, others also saw the commercial potential associated with
patenting isolated sequences. This led to a race to file for patent
applications, with patents on DNA sequences being issued to entities
including: University of California; U.S. Government; Aventis;
GlaxoSmithKline; Incyte Genomics, Inc.; Bayer; Chiron; Genentech;
Amgen; Human Genome Sciences, Inc.; Wyeth; Merck; Applera;
University of Texas; Novartis; Johns Hopkins University; Pfizer;
Massachusetts General Hospital; Novo Nordisk; Harvard University;
Stanford University; Lily; Affymetrix, Inc.; Cornell University; Salk
150. Changingthe Face of Medicine, supra note 21.
151. Nugent, supra note 17.
152. Biography 39: John Craig Venter (1946 -), supra note 142.
153. Hilts, supra note 19.
154. Joseph P. Pieroni, The Patentabilityof Expressed Sequence Tags, 9 FED. CIR. B.J. 40116 (2000), available at http://www.fitzpatrickcella.com/DB6EDC/assets/files/News/attachment
148.pdf.
155. Hilts, supranote 19 (in part as a protest against the patenting of human genes).
156. Craig Venter, supra note 26, Discovery.
157. Selim & Duncan, supra note 143.
158. Craig Venter, supra note 26, Human Genome Project.
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Institute; Columbia University; University of Wisconsin; MIT;
Washington University; University of Pennsylvania; Rockefeller
University; Baylor College of Medicine; Dana Farber Cancer Institute;
Scripps; Thomas Jefferson University; University of Michigan;
California Institute of Technology; University of Washington;
University of Chicago; University of Utah; State University of New
York; New York University; Michigan State University; Duke
University; University of Florida; and Whitehead.' 59
3. Academic Institutions File for Patents
Only a decade prior to the formation of the NCHGR, Congress had
passed the Bayh-Dole Act,' 60 which allowed academic institutions to
retain title to patents on inventions that resulted from federal funding.' 6 1
Now owning the patents, these academic institutions could now license
their patents for royalty-generating revenues.162 This type of ownership
structure led to academic institutions filing for patent protection on
numerous inventions in a wide variety of disciplines. 6 3
The field of genetic research was no exception. By November 2005,
there were 38,929 DNA patents,1 64 of which 10,824 were owned by 30
companies, 165 including 13 academic institutions.16 6 These academic
institutions accounted for ownership of 3,772 DNA patents;167 over a
third of the DNA patents owned by the top-30 entities.
Relevant to this Article, the University of Pennsylvania and
Columbia University are included among the top-30 entities.' 68 When
narrowed to only academic institutions (as compared to all entities), the
University of Pennsylvania, Columbia University, Yale University, and
New York University are counted among the top-30,169 each of these

159. Lori Pressman et al., The Licensing of DNA Patents by Large U.S. Academic
Institutions:An EmpiricalSurvey, NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION, Aug.

13, 2009, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726797/.
160. 35 U.S.C. § 200 (2006).
161. 35 U.S.C. § 202 (2006).
162. Bayh-Dole Act, WIKIPEDIA.ORG, http://en.wikipedia.org/wikilBayh-Dole Act (last
visited Sept. 23, 2011).
163. A cursory search of patents using the search criteria "AN/(University)" reveals 65,883
results for patents in the entire database. Narrowing this to patents filed after Dec. 12, 1980
(when the Bayh-Dole Act was passed), we see that 63,389 of those patents (or 96.2%) were filed
after the passage of the Bayh-Dole Act.
164. Pressman et al., supra note 159.
165. Id.
166. Id.
167. Id.
168. Id.
169. Id.
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institutions claiming ownership of over 75 DNA patents.' 70
III. ISSUED PATENTS AND PENDING PATENT APPLICATIONS ON
ISOLATED SEQUENCES

Our ability to create has outreachedour ability to use wisely the
products of our invention.17 1
Having provided some background on why the issues in the BRCA
Lawsuit are significant, and how the legal tensions mimic the tension in
the scientific community, we now turn our attention to the data. In
particular, we discuss the parameters for gathering our data, and the
specific results derived from our methodology.
A. Methodology
As noted earlier, we utilized a two-fold query: (a) what happens
when an inventor applies for a patent for an invention that the inventor
does not believe to be patentable, yet withholds that information from
the USPTO; and (b) what happens when an entity that is substantively
involved in prosecuting the patent has information that the subject
matter sought to be patented is non-statutory, yet withholds that
information from the USPTO.' 7 2
Specifically, in the context of the BRCA Lawsuit, the individual
plaintiffs took the position that isolated-gene patents are non-statutory
subject matter. 7 3 Insofar as the plaintiffs' arguments with reference to
isolated genes will apply equally to all isolated sequences, we defined
our universe of relevant subject matter to be all isolated sequences.
Namely, we defined isolated sequence to include any nucleotide, amino
acid, peptide, or polypeptide sequence that has been isolated from its
native state, or their equivalents. As such, our search encompassed any
gene (either the DNA or its RNA transcript and including other RNA
molecules such as siRNA or miRNA which can be encoded by genes
themselves or are natural products of RNAi), protein sequence, or any
fragments thereof.
First, our inquiry related to individual inventors. Thus, insofar as the
relevant individual plaintiffs were employed by Yale, Emory, UPenn,
170. Id.
171. Whitney M. Young, American activist.
172. Supra Part I.
173. See generally Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office,
No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009) (all of plaintiffs' filings uniformly allege that
isolated genes and corresponding methods are not patentable subject matter).
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Columbia, and NYU, we sought to determine whether these individual
plaintiffs were inventors on isolated-sequence-related patents or patent
applications. Thus, we conducted a search on the USPTO database for
all issued patents 74 and published patent applications' 7 5 in which: (a)
the assignee included Yale, Columbia, UPenn, NYU, or Columbia; and
(b) the inventors included Haig Kazazian, Arupa Ganguly, Wendy
Chung, Harry Ostrer, David Ledbetter, Stephen Warren, Ellen Matloff,
or Elsa Reich.176 We then examined each patent claim from the
resulting issued patents and published applications to determine whether
or not the claim was indeed directed to an isolated sequence.
Second, our inquiry related to the entities that are substantively
involved in filing and prosecuting patent applications on behalf of
inventors. For academic institutions, these individuals are the
technology transfer office (TTO) personnel of their respective academic
institutions. Giving the TTO personnel the benefit of the doubt, we
presumed that the TTO personnel were unaware of their own inventors'
positions until May 12, 2009, the filing date of the BRCA Lawsuit, 7 7 at
which time the plaintiffs' position became public knowledge.
Additionally, because the TTO personnel's duty to disclose manifests
itself only while the patent application is pending before the USPTO,"'
we limited this part of our search to the relevant period in which the
we
duty to disclose would apply. Thus, for this part of the quer7,
8
that
applications'
patent
published
and
searched issued patents
were: (a) pending at the USPTO between the dates of May 12, 2009 and
July 19, 2011; (b) assigned to UPenn, Columbia, NYU, Emory, or Yale;
(c) with claims having any of the following terms: SEQ ID, sequence,
gene, protein, isolated, nucleic, RNA, DNA, peptide, polynucleotide,
polypeptide, epitope, or antibody.
174. The search for issued patents was conducted at the following website: http://patft.
uspto.gov/netahtml/PTO/search-adv.htm.
175. Id.
176. The exact search parameters were "AN/(Yale OR Pennsylvania OR Emory OR
Columbia OR York) AND IN/((Haig AND Kazazian) OR (Arupa AND Ganguly) OR (Wendy
AND Chung) OR (Harry AND Ostrer) OR (David AND Ledbetter) OR (Stephen AND Warren)
OR (Ellen AND Matloff) OR (Elsa AND Reich))."
177. Ass'nfor MolecularPathology,No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009).
178. MPEP § 2001.04 ("The duty to disclose information, however, does not end when an
application becomes allowed but extends until a patent is granted on that application.").
179. The search for issued patents was conducted at the following website: http://patft.
uspto.gov/netahtml/PTO/search-adv.htm.
180. The search for published patent applications was conducted at the following website:
http://appftl.uspto.gov/netahtml/PTO/search-adv.html.
181. The exact search parameters for the issued patents were "AN/("Yale University" OR
"University of Pennsylvania" OR "Emory University" OR "Columbia University" OR "New
York University") AND ACLM/((SEQ AND ID) OR sequence OR gene OR protein OR
isolated OR nucleic OR RNA OR DNA OR peptide OR polynucleotide OR polypeptide OR
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With reference to the published patent applications, we did not
perform a claim-by-claim analysis, because each claim's final status
was unknown and would not be known until the patent issued. As such,
our analysis for published patent applications produced only a raw
number that signaled a potential problem, should the claim eventually
issue substantially-unmodified from how the claim was published. In
other words, since claims have a tendency to be amended during
prosecution, and since many patent applications are abandoned during
prosecution, it made no sense to analyze the claims in the published
patent applications, rather than waiting for the patent to issue and then
analyzing the claims in the issued patent.
B. Results
We set forth our results below in three separate categories for each
of the academic institutions. First, if there were any issued patents or
published patent applications that listed one of the named plaintiffs as
inventors, then we noted those issued patents and published patent
applications with particularity. Second, we listed all of the isolatedsequence-related patents that the USPTO issued during the relevant time
period. Third, we listed all of the isolated-sequence-related published
patent applications for the relevant time period.
1. The University of Pennsylvania
Because it has previously been embroiled in litigation with Myriad,
we begin with the University of Pennsylvania.' 82
a. Specific Issued Patents and Published Patent
Applications of Interest
The two named plaintiffs from the University of Pennsylvania are
Dr. Haig Kazazian and Dr. Arupa Ganguly. 183 During the pendency of
the lawsuit, Dr. Haig Kazazian had a published patent application that
was pending in the USPTO.18 4 That published application was directed
epitope OR antibody) AND ISD/20090512->20110729"; the search parameters for published
applications were "AN/('Yale University' OR 'University of Pennsylvania' OR 'Emory
University' OR 'Columbia University' OR 'New York University') AND ACLM/((SEQ AND
ID) OR sequence OR gene OR protein OR isolated OR nucleic OR RNA OR DNA OR peptide
OR polynucleotide OR polypeptide OR epitope OR antibody)."
182. Myriad Genetics v. Univ. of Pa., 2:98-cv-00829 (D. Utah 1998).
183. BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009), Complaint, Doc.
No. 1.
184. U.S. Published Application Number US 2003-0121063 Al, pending between Aug. 9,
2002 and Feb. 28, 2011.
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to a "method of isolating a nucleic acid molecule from a genome of an
During the pendency of that patent
offspring of an animal."
application, Kazazian filed a declaration, under penalty of perjury,
acknowledging the obligation to disclose information that is material to
patentability under 37 C.F.R. § 1.56.186
Insofar as Kazazian believed that "[r]emoving a product of nature
from its natural location does not make it any less a product of
nature[,]"' 8 7 Kazazian's own method of "isolating a nucleic acid
molecule" is an unpatentable product of nature. Also, because Kazazian
acknowledged under oath the duty to disclose material information
under Rule 56, Kazazian had an obligation to disclose relevant portions
of the pleadings and filings from the Southern District of New York.' 8
Kazazian did not disclose this information to the USPTO during the
pendency of Kazazian's patent application.
Dr. Ganguly is the inventor on U.S. Patent Number 5,874,212 ("the
'212 patent"), which includes a claim that is directed to a "method for
detecting one or more base pair mutations in a nucleic acid
sequence."l89 During the pendency of the application that eventually

matured into the '212 patent, Ganguly executed a declaration,
acknowledging under penalty of perjury the duty to disclose material
information under Rule 56.1 0 To the extent that Ganguly believed that
genetic alterations are caused by nature,191 Ganguly had a duty to
disclose that information to the USPTO. Ganguly did not disclose this
information to the USPTO during the pendency of the application that
eventually matured into the '212 patent.
Insofar as both the Kazazian patent application and the Ganguly
patent were assigned to the University of Pennsylvania, the person that
was substantively involved in the prosecution was the Technology
Licensing Officer (TLO) at the University of Pennsylvania Center for
Technology Transfer (UPenn-CTT).19 2 Thus, not only did Kazazian and
185. Id. claim 8, as originally submitted.
186. Id.
187. BRCA Lawsuit, Complaint 1 5 1.
188. See 37 C.F.R. § 1.56.
189. U.S. Patent No. 5,874,212, claims I & 8 (filed June 6, 1995).
190. Id. File History.
191. BRCA Lawsuit, Doc. No. 63, Plaintiffs' Rule 56. 1 Statement of MaterialFacts IT 60
& 99 (citing D. Sulston 27; D. Chung 10).
192. Center For Technology Transfer, UNIVERSITY OF PENNSYLVANIA, http://www.ctt.
upenn.edu/index.html (last visited Aug. 15, 2011); About CTF, CENTER FOR TECHNOLOGY
TRANSFER, UNIVERSITY OF PENNSYLVANIA, http://www.ctt.upenn.edu/whoweare.html (last
visited Aug. 15, 2011); Process, CENTER FOR TECHNOLOGY TRANSFER, UNIVERSITY OF

PENNSYLVANIA, http://www.ctt.upenn.edu/techtransfer.html (last visited Aug. 15, 2011); After
Disclosure,

CENTER

FOR

TECHNOLOGY

TRANSFER,

UNIVERSITY

http://www.ctt.upenn.edu/afterdisclosure.html (last visited Aug. 15, 2011).

OF

PENNSYLVANIA
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Ganguly have an obligation to disclose material information, but also
the UPenn-CCT TLO had an obligation under Rule 56 to disclose
information that the TLO knew to be material to patentability.
Specifically, since Kazazian and Ganguly's position was publicly
known during the pendency of the Kazazian patent application, the TLO
had an obligation to disclose relevant portions of the BRCA Lawsuit
filings to the USPTO with reference to the Kazazian application. No
such information was disclosed by the TLO to the USPTO.
More generally, Kazazian and Ganguly's statements that "genes are
products of nature" were material to all pending patent applications
directed to genes and their associated methods. Thus, the TLO had an
obligation under Rule 56 to disclose the relevant filings from the
Southern District of New York in all of UPenn's pending patent
applications that were directed to genes and their associated methods.
b. Issued Patents
There were a total of 40 patents issued to the University of
Pennsylvania which satisfied our search criteria.1 93 Of those issued
patents, 20 patents included claims that were directed to isolated
sequencesl94 and 23 included claims that were directed to methods
involving isolated sequences.195 Of these, 3 issued patents included
claims that are analogous to the claims that were invalidated in the
Southern District of New York. 19 6
c. Published Patent Applications
There were a total of 298 published patent applications for the
University of Pennsylvania which satisfied our search criteria.'
193. U.S. Patent Nos. 7972796; 7943587; 7943324; 7939063; 7910107; 7906624;
7906111; 7902341; 7879569; 7858097; 7855064; 7851452; 7847090; 7838277; 7794729;
7790449; 7781566; 7750143; 7745577; 7741111; 7736852; 7704736; 7700344; 7696307;
7674895; 7662629; 7662570; 7662396; 7655238; 7651997; 7645744; 7638598; 7635479;
7625751; 7592012; 7588930; 7569543; 7569218; 7560116 & 7553955.
194. U.S. Patent Nos. 7906624; 7847090; 7781566; 7750143; 7745577; 7741111;
7700344; 7674895; 7662629; 7662396; 7655238; 7651997; 7645744; 7638598; 7635479;
7625751; 7592012; 7569543; 7560116 & 7553955.
195. U.S. Patent Nos. 7972796; 7943587; 7943324; 7939063; 7910107; 7906111;
7902341; 7858097; 7855064; 7851452; 7838277; 7794729; 7790449; 7736852; 7704736;
7696307; 7662629; 7662570; 7662396; 7655238; 7635479; 7588930 & 7569218.
196. U.S. Patent No. 7741111 (claims 1, 9, and 13 are directed to isolated nucleotide
sequences that correspond to native human PNCK); 7696307 (claim 1 is directed to a native
polypeptide fragment of ADAMTS-1) & 7625751 (claims 3, 4, 5, 8, and 10 are directed to
native human West Nile Virus Core Protein/Capsid Interacting Protein human WIP- 1).
197. Search conducted on Sept. 23, 2011, using search criteria: "AN/('University of
Pennsylvania') AND ACLM/((SEQ AND ID) OR sequence OR gene OR protein OR isolated
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2. Columbia University
From Columbia University, we have Dr. Wendy Chung,198 who filed
an affidavit in the Southern District of New York, stating that "genes
are products of nature and not inventions of man." 99
a. Specific Patent of Interest
Of specific interest in this Part is U.S. Patent Number 7,339,028
('028 patent), listing Chung as an inventor.200 Specifically, the '028
patent claims an "isolated human mahoganoid polypeptide comprisin
amino acids the sequence of which is set forth in SEQ ID NO:8[,]" 2
which includes 494 amino acids.20 2 In the definitions, Chung notes that
the mutation of the mahoganoid polypeptide is non-wild-type,2 0 3
inferring that the claimed polypeptide is wild-type or naturally
occurring.
During the pendency of the application that eventually matured into
the '028 patent, Chung executed a declaration, acknowledging under
penalty of perjury the duty to disclose material information under Rule
56.
To the extent that Chung believed her polypeptide to be a
"product of nature," 205 and to the extent that Chung executed the oath
under Rule 56, Chung knew that she had a duty to disclose to the
USPTO that her patent claimed non-statutory subject matter. Chung did
not disclose this information to the USPTO.
Because Chung's patent was assigned to The Trustees of Columbia
20
University in the City of New York,206
the Columbia Technology
Ventures TLO was substantively involved in the prosecution of Chung's
patent application.207 Thus, under Rule 56, that TLO also had a duty to
OR nucleic OR RNA OR DNA OR peptide OR polynucleotide OR polypeptide OR epitope OR
antibody)."
198. BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009), Complaint, Doc.
No. 1.
199. Id. Doc. Nos. 40 (Declaration of Wendy K. Chung (Columbia)) & 78.
200. U.S. Patent No. 7,339,028 (filed June 6, 2003).
201. Id.
202. Id.
203. Id.
204. Id. File History.
205. BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009), Doc. No. 63,
Plaintiffs'Rule56.1 Statement of MaterialFacts 60 & 99 (citing D. Sulston 27; D. Chung

10).
206. U.S. Patent No. 7,339,028.
207. Working with Tech Ventures, COLUMBIA TECHNOLOGY VENTURES, http://techventures.
columbia.edu/inventors/working-with-techventures (last visited Aug. 16, 2011); Submit an
Invention, COLUMBIA TECHNOLOGY VENTURES, COLUMBIA UNIVERSITY, http://techventures.

columbia.edulinventors/submit-an-invention (last visited Aug. 16,2011).
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disclose material information to the USPTO.2 0 8 To the extent that the
TLO knew of this information from one of its own inventors, and to the
extent that Chung's sworn statement in the Southern District of New
York was inconsistent with the patentability of isolated sequences, the
TLO had an affirmative obligation to disclose that information in all of
the pending applications directed to isolated sequences for which the
TLO was substantively involved. 20 9 The TLO did not disclose this
information to the USPTO.
b. Issued Patents
There were a total of 14 patents issued to the Columbia University,
which satisfied our search criteria. 210 Of those issued patents, 7 patents
included claims that were directed to isolated sequences, 2 and 9
included claims that were directed to methods involving isolated
sequences.212 Of these, 1 issued patent included a claim that is
the claims that were invalidated in the Southern District of
analogous to
213
York.
New
c. Published Patent Applications
There were a total of 229 published patent applications for the
Columbia University which satisfied our search criteria.2 14
3. Yale University
Unlike the University of Pennsylvania and Columbia University, the
University employees from Yale are not inventors on any issued patents
or published patent applications. As such, the connection between
Yale's Office of Cooperative Research (Yale-OCR) and the statements
by the Yale University employees is more tenuous. Nevertheless, to the
extent that that Yale-OCR employees were aware of any fact that
208.
209.
210.
7807620;
211.

37 C.F.R. § 1.56.
Id.
U.S. Patent Nos. 7968126; 7947279; 7932066; 7888326; 7884189; 7863424;
7803932; 7772367; 7662919; 7662794; 7645734; 7582740 & 7579330.
U.S. Patent Nos. 7947279; 7932066; 7884189; 7803932; 7772367; 7662919 &

7582740.
212. U.S. Patent Nos. 7968126; 7888326; 7863424; 7807620; 7803932; 7662794;
7645734; 7582740 & 7579330.
213. U.S. Patent No. 7947279 (claim 1 is directed to fragments of human Uch-L1).
214. Search conducted on Sept. 23, 2011, using search criteria: "AN/('Columbia
University') AND ACLM/((SEQ AND ID) OR sequence OR gene OR protein OR isolated OR
nucleic OR RNA OR DNA OR peptide OR polynucleotide OR polypeptide OR epitope OR
antibody)."
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"refutes or is inconsistent with a position the applicant takes before the
PTO with respect to patentability[,]" 2 15 the Yale-OCR employees were
required to disclose that to the USPTO. .
a. Issued Patents
There were a total of 23 Patents issued to Yale University which
satisfied our search criteria. 16 Of those issued patents, 7 patents
included claims that were directed to isolated sequences, 2 17 and 17
included claims that were directed to methods involving isolated
sequences. 218 Of these, I issued patent included claims that are
analogous to the claims that the Court of Appeals for the Federal Circuit
found to be invalid, 2 19 and 5 issued patents included claims that are
analogous to the claims that were invalidated in the Southern District of
New York. 220
b. Published Patent Applications
There were a total of 229 published patent applications for Yale
University, which satisfied our search criteria.2 2 1

215. Id.
216. U.S. Patent Nos. 7985583; 7985538; 7932067; 7928216; 7928071; 7893034;
7893032; 7888089; 7872094; 7858084; 7838223; 7829672; 7794931; 7794926; 7790463;
7790404; 7776826; 7776518; 7741306; 7700095; 7553821; 7553674 & 7538089.
217. U.S. Patent Nos. 7985583; 7928216; 7893032; 7888089; 7829672; 7794931 &
7538089.
218. U.S. Patent Nos. 7985538; 7932067; 7928071; 7893034; 7893032; 7872094;
7858084; 7838223; 7794926; 7790463; 7790404; 7776826; 7776518; 7741306; 7700095;
7553821 & 7553674.
219. U.S. Patent No. 7790463 (Central to the purpose of claims 1, 8, and 9 is only the
mental steps of comparing gene expression profiles to determine the probability of developing
preeclampsia. The claims do not conform to standard set in Promethus. Although determining
the expression levels of the biomarkers may constitute a transformation, this is not central to the
purpose of the claims. Therefore, it would be inappropriate to read this into the claims, under the
Federal Circuit's analysis in BRCA Lawsuit. Without this transformative step, the claim would
be invalid under the Federal Circuit's opinion).
220. U.S. Patent Nos. 7985583 (claim 1 is directed to encoding nucleotide sequence for a
native Chlamydomonas intraflagellar transport particle protein 88); 7893034 (claim 14 is
analogous to claim 20 of the Myriad '282 Patent); 7790463 (see supra note 219); 7553674
(claims 3, 4, 5, 7, 8, and 9 are analogous to claim '20 of the Myriad '282 Patent in that the
screening assay is based on observing a physical characteristic; in this case, for example, cell
motility, as recited in claim 5) & 7538089 (claim 6 is directed to a native anti-inflammatory
peptide sequence).
221. Search conducted on Sept. 23, 2011, using search criteria: "AN/(Yale University')
AND ACLM/((SEQ AND ID) OR sequence OR gene OR protein OR isolated OR nucleic OR
RNA OR DNA OR peptide OR polynucleotide OR polypeptide OR epitope OR antibody)."
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4. New York University
Similar to Yale University's employees, the University employees
from New York University (NYU), Dr. Ostrer and Prof. Reich, are not
inventors on any issued patents or published patent applications. Thus,
there is a greater degree of separation between NYU's Office of
Industrial Liaison/Technology Transfer (TTO) and the statements by
Ostrer and Reich. However, to the extent that any NYU-TTO employee
that was substantively involved in the prosecution of NYU's isolatedsequence patents was aware of Ostrer or Reich's statements, the NYUTTO employee was required to disclose Ostrer and Riech's statements
to the USPTO.2 2 2
a. Issued Patents
There were a total of 39 patents issued to the New York University,
which satisfied our search criteria.223 Of those issued patents, 19 patents
included claims that were directed to isolated sequences 2 24 and 22
included claims that were directed to methods involving isolated
sequences.225 Of these, 9 issued patents included claims that are
analogous to the claims that were invalidated in the Southern District of
New York. 226

222. 37 C.F.R. § 1.56.
223. U.S. Patent Nos. 7928068; 7919603; 7919250; 7902327; 7887808; 7884067;
7879977; 7847085; 7838275; 7833774; 7807182; 7807147; 7795427; 7790673; 7785606;
7776341; 7772202; 7771726; 7767417; 7750050; 7745141; 7744885; 7741298; 7737250;
7732592; 7709454; 7705126; 7705118; 7696308; 7691964; 7666587; 7662783; 7638319;
7638304; 7632816; 7632801; 7622121; 7618933 & 7563868.
224. U.S. Patent Nos. 7919603; 7902327; 7884067; 7879977; 7847085; 7807182;
7785606; 7776341; 7772202; 7737250; 7732592; 7705126; 7705118; 7696308; 7691964;
7638304; 7622121; 7618933 & 7563868.
225. U.S. Patent Nos. 7928068; 7919250; 7887808; 7838275; 7833774; 7807182;
7807147; 7795427; 7790673; 7771726; 7767417; 7750050; 7745141; 7744885; 7741298;
7709454; 7666587; 7662783; 7638319; 7632816; 7632801 & 7618933.
226. U.S. Patent Nos. 7919603 (claims 1 through 4 are directed to nucleotide sequences for
human HSRI); 7884067 (claims 1 and 3 are directed to a native peptide fragment of human PSI
and other cadherins); 7807182 (claim I is directed to native peptide fragments); 7776341
(claims 1, 5, 16, and 29 are directed to native peptide sequences); 7737250 (claims 1, 4, and 6
are directed to a native peptide from a Ll-CAM family member protein); 7705126 (claim I is
directed to a polypeptide which is a fragment of the rat FP-1); 7691964 (claims 1 through 7 are
directed to the encoding nucleic acid sequences and native peptide sequences for a contact
inhibitory factor); 7622121 (claim 1 is directed to an amino acid sequence of a native heat shock
protein) & 7563868 (claims 1 and 2 are directed to a native NRF3 polypeptide sequence).
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b. Published Patent Applications
There were a total of 291 published patent agplications for New
York University, which satisfied our search criteria.
5. Emory University
The two relevant individuals from Emory University are Drs.
Ledbetter and Warren.228 Dr. Ledbetter filed an affidavit in the BRCA
Lawsuit, expressly stating that "[g]enes are products of nature and not
inventions of man." 229
a. Specific Patents of Interest
Ledbetter is an inventor on U.S. Patent Number 6,143,504,230 and
Warren is an inventor on U.S. Patent Number 7,432,052.231 As
originally filed, Warren's patent application included a claim to "[a]n
isolated anti-fragile X mental retardation (anti-FMRP) monoclonal
antibody raised in an FMRP knock-out mouse." 232
During the pendency of the application that eventually matured into
the '504 patent, Ledbetter executed a declaration, acknowledging under
penalty of perjury the duty to disclose material information under Rule
56. 233 Similarly, Warren executed a declaration in connection to his
application for the '052 patent.23 4 To the extent that Ledbetter and
Warren believed their claimed inventions to be non-statutory subject
matter, and to the extent that Ledbetter and Warren executed their
respective oaths under Rule 56, Ledbetter and Warren knew of their
duty to disclose to the USPTO that their respective patents claimed nonstatutory subject matter. Neither Ledbetter nor Warren disclosed such
information to the USPTO.
227. Search conducted on Sept. 23, 2011, using search criteria: "AN/('New York
University') AND ACLM/((SEQ AND ID) OR sequence OR gene OR protein OR isolated OR
nucleic OR RNA OR DNA OR peptide OR polynucleotide OR polypeptide OR epitope OR
antibody)."
228. BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009), Complaint, Doc.
No. 1.
229. Id. Doc. Nos. 48 & 86 27.
230. Although Ledbetter's patent claims "isolated primers" (claims 15-18), which are
laboratory-created sequences, we specifically note this patent because Ledbetter, in opposing
Myriad's claims to cDNA, took the position that cDNA was not patentable subject matter, even
though cDNA is also a laboratory-created sequence similar to primers.
231. U.S. Patent Number 7,432,052.
232. U.S. Patent Application Serial No. 10/495,728, claim 40 (as originally filed).
233. U.S. Patent No. 6,143,504, File History.
234. U.S. Patent No. 7,432,052, File History.
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Insofar as the Warren patent was assigned to Emory University,2 3 5
the Emory University TLO was substantively involved in the
prosecution of Warren's patent application. 236 Thus, under Rule 56, that
TLO also had a duty to disclose material information to the USPTO.2 37
b. Issued Patents
The USPTO issued a total of 10 patents to Emory University which
satisfied our search criteria.2 3 8 Of those issued patents, 6 patents
included claims that were directed to isolated sequences239 and 6
included claims that were directed to methods involving isolated
sequences.240 Of these, 2 issued patents included claims analogous to
the claims
that were invalidated in the Southern District of New
24
York. 1
c. Published Patent Applications
A total of 63 published patent applications for Emory University
satisfied our search criteria. 24
IV. INEQUITABLE CONDUCT

Things gained through unjustfraud are never secure.243
With all of these issued patents and published patent applications in
mind, we now turn to the law of inequitable conduct, focusing
specifically on Therasense, Inc. v. Becton, Dickinson and Co.244
235. Id.
236. About Us, supra note 128.
237. 37 C.F.R. § 1.56.
238. U.S. Patent Nos. 7892532; 7833978; 7825228; 7795017; 7781574; 7741117;
7691814; 7576181; 7560107 & 7537902.
239. U.S. Patent Nos. 7833978; 7825228; 7795017; 7781574; 7691814 & 7560107.
240. U.S. Patent Nos. 7892532; 7825228; 7781574; 7741117; 7576181 & 7537902.
241. U.S. Patent Nos. 7825228 (claim I is directed to a naturally occurring (detected in a
cDNA library) variant nucleotide sequence of LMP-1) & 7691814 (claim I is directed to a
sequence "which naturally occurs in the amino acid sequence of the LMP-3 protein," according
to the written description of the '228 patent).
242. Search conducted on Sept. 23, 2011, using search criteria: "AN/('Emory University')
AND ACLM/((SEQ AND ID) OR sequence OR gene OR protein OR isolated OR nucleic OR
RNA OR DNA OR peptide OR polynucleotide OR polypeptide OR epitope OR antibody)."
243. Sophocles.
244. Slip Op., Case Nos. 2008-1511, -1512, -1513, -1514, -1595 (Fed. Cir., decided May
25,2011).
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order to understand how Therasense impacts our analysis of the relevant
institutional patents, we first analyze various aspects of the law prior to
Therasense. Thereafter, we examine the court's latest pronouncement
on inequitable conduct, as set forth in Therasense.
A. Inequitable ConductPriorTo Therasense
In this Part, we discuss various aspects of inequitable conduct prior
to Therasense. In particular, we focus on: (a) the duty to disclose, as
imposed by 37 C.F.R. § 1.56; and (b) the doctrine of infectious
unenforceability, as set forth in various legal opinions.
1. The Duty of Disclosure under Rule 56
Under 37 C.F.R. § 1.56 (Rule 56), everyone associated with the
filing and prosecution of a United States patent application owes a duty
to disclose any material information to the USPTO.24 5 According to
Rule 56 of the Code of Federal Regulations, this duty is imposed on the
following groups:
(1) Each inventor named in the application; (2) Each attorney or
agent who prepares or prosecutes the application; and (3) Every
other person who is substantively involved in the preparationor
prosecution of the application and who is associated with the
inventor, with the assignee or with anyone to whom there is an
obligation to assign the application." 246
In Avid Identification Sys., Inc. v. Crystal Import Corp.,2 4 7 the Court
of Appeals for the Federal Circuit addressed who would be
encompassed under the third prong of "[e]very other person who is
substantively involved in the preparation or prosecution of the
application." 2 48 The Avid court defined "'substantively involved' [as]
... involvement relate[d] to the content of the application or decisions

related thereto, and that the involvement is not wholly administrative or
secretarial in nature." 249 This language is intended to make clear that the
duty is not imposed on typists, clerks, secretaries, and other similarly
245. 37 C.F.R. § 1.56(a) ("Each individual associated with the filing and prosecution of a
patent application has a duty of candor and good faith in dealing with the Office, which includes
a duty to disclose to the Office all information known to that individual to be material to
patentability .... ) (emphasis added).
246. Id. (c).
247. 603 F.3d 987 (Fed. Cir. 2010).
248. Id. at 974.
249. Id. (citing MPEP § 2001.01).
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situated persons associated with a patent application. 2 50
According to the Manual of Patent Examining Procedures (MPEP),
this duty is imposed on individuals, not entities or corporations. 2 5 1 For
example, in Avid Identification Sys., Inc. v. Crystal Import Corp.,25 2 the
company (Avid) that designed and marketed biocompatible radio
frequency chips for implantation into animals, sued its competitor
(Datamars) for patent infringement. 253 Avid's founder and president,
veterinarian Dr. Hannis Stoddard, demonstrated some of Avid's
technology at a trade show in April 1990.254 Avid filed for patent '326
in August 1991 and withheld the information regarding the 1990
demonstration.2 5 5 The USPTO issued the '326 patent in August 1993.256
The district court held Avid's patent unenforceable due to
inequitable conduct, finding that the demonstration at the trade show
was material prior art under 35 U.S.C. § 102(b) and that Avid withheld
this information with deceptive intent.257 Avid appealed that the
demonstration was material and that Dr. Stoddard owed a duty of
disclosure to the USPTO.2 58 The Court of Appeals for the Federal
Circuit affirmed and held that the definition of "substantively involved"
included "involvement relate[d] to the content of the application or
decisions related thereto, and that the involvement is not wholly
administrative or secretarial in nature." 259
Thus, in the context of academic institutions and their respective
technology transfer offices (TTO), this duty under Rule 56 would fall
on the individuals within the TTO who are involved with the content or
decision-making related to a patent application. This is because the
individuals within the TTO coordinate the patent application process,
relying on the inventors' participation and their respective patent
attorneys. As described, the relationship created between inventor and
the TTO makes it such that the individuals within these offices are
"substantively involved in the preparation or prosecution of the [patent]
application."

250. MPEP § 2001.01.
251. Id.; see also Exergen Corp. v. Wal-Mart Stores, Inc., 575 F.3d 1312, 1329 (Fed. Cir.
2009).
252. Avid Identification Sys., Inc. v. Crystal Import Corp., 603 F.3d 987 (Fed. Cir. 2010).
253. Id. at 969.

254. Id. at 970.
255. Id.
256. Id.
257. Id.

258. Id. at 972.
259. Id. at 974 (citing MPEP § 2001.01).
260. 37 C.F.R. § 1.56.
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2. Infectious Unenforceability
The law is also clear that a finding of inequitable conduct in
procuring any claim within a patent will result in the unenforceability of
the entire patent.261 This doctrine is often termed "infectious
unenforceability." 262
Courts have also
extended
infectious
unenforceability beyond the claims of a single patent and have applied it
to other patents that are "genealogically related to the original
application as to which inequitable conduct has been found." 263 In other
words, inequitable conduct in procuring a single claim within a single
patent can result in the unenforceability of an entire family of patents.
This is because "[t]he duty of candor and good faith extends throughout
the patent's entire prosecution history." 65 Thus, "[i]n determining
inequitable conduct, a . .. court may look beyond the final claims [of a

patent] to their antecedents[,]"
which include amendments,
continuations, and divisionals.2 66
For example, in Consolidated Aluminum Corp. v. Foseco Int'l,
Ltd.,267 the patent holder (Consolidated Aluminum) sued for
infringement of 6 patents relating to the manufacture and use of ceramic
foam filters for molten metal. 26 At trial, the court found parent patent
('917 patent) unenforceable due to inequitable conduct. Consolidated
Aluminum had failed to disclose the best mode and some prior art at the
time of filing. 270 With respect to the best mode, Consolidated
Aluminum not only intentionally omitted the best mode in the '917
patent, but also disclosed a fictitious and inoperable mode.27 Later,
Consolidated Aluminum claimed this known and omitted best mode in a
second patent ('363 patent, which was not asserted in the underlying
suit). 27 2
Due to Consolidated Aluminum's failure to disclose and the
fabrication of a fictitious and inoperable mode, the trial court found 3 of
the other 5 patents in suit273 to also be unenforceable due to a "broad
261. Kingsdown Med. Consultants, Ltd. v. Hollister, Inc., 863 F.2d 867 (Fed. Cir. 1988).
262. Baxter Int'l, Inc. v. McGaw, Inc., 958 F. Supp. 1313, 1315 (N.D. Ill. 1997), aff'd in
part, rev'd in part, 149 F.3d 1321 (Fed. Cir. 1998).
263. Id.
264. Nilssen v. Osram Sylvania, Inc., 504 F.3d 1223, 1230 (Fed. Cir. 2007).
265. Fox Indus. v. Structural Pres. Sys., 922 F.2d 801, 803 (Fed. Cir. 1991).
266. Id.
267. 910 F.2d 804 (Fed. Cir. 2005).
268. Id. at 806.
269. Id. at 807.
270. Id.
271. Id.
272. Id.

273. Namely, the '081 patent, the '212 patent, and the '303 patent.
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pattern of inequitable conduct." 274 The Consolidated Aluminum court
applied the "unclean hands doctrine" of Keystone DrillerCo. v. General
Excavator Co., 275 and Precision Instrument Mfg. Co. v. Automotive
Maintenance Machinery Co.276 The court held that Consolidated
Aluminum's inequitable conduct so soiled the patent holder's hands that
it rendered the other patents 27727
equally unenforceable.2 7 8
Despite the infectiousness of inequitable conduct, this doctrine does
not extend to any and all patents in a patent holder's portfolio. 2 79
Rather, there must be a relatedness, or relationship, between the claim
procured by inequitable conduct and the other claims or patents within

the patent family. 280
B. The Significance ofTherasense
With this backdrop, we now turn to Therasense, specifically
reviewing how Therasense impacted the law of inequitable conduct. We
will examine the three issued opinions: the majority opinion, 28 1 the
concurrence, 28228
and the dissent.2 83
We begin with explaining why the Court of Appeals for the Federal
Circuit granted en banc review to Therasense. The court stated its
objective as "redirect[ing] a doctrine that ha[d] been overused to the
detriment of the public."
Specifically, the court found that charges of
inequitable conduct "ha[d] been overplayed, [were] appearing in nearly
every patent suit, and [were] cluttering up the patent system."285 As a
result, the "habit of charging inequitable conduct in almost every major
patent case ha[d] become an absolute plague[,]" 2 86 where "[r]eputable
lawyers seem[ed] to feel compelled to make the charge against other

274. Id.
275. 290 U.S. 240, 245-46 (1933).
276. 324 U.S. 806, 815 (1945).
277. '081 patent, '212 patent, & '303 patent.
278. PrecisionInstrument Mfg., 324 U.S. at 809.
279. Pharmacia Corp. v. Par Pharm., Inc., 417 F.3d 1369, 1375 (Fed. Cir. 2005).
280. See Consol. Aluminum Corp. v. Foseco Int'l, Ltd., 910 F.2d 804, 809-10 (Fed. Cir.
2005).
281. Therasense, Inc. v. Becton, Dickinson & Co., Slip Op., Docket No. 2008-1511, -1512,
-1513, -1514, -1595 (Fed. Cir., decided May 25, 2011).
282. Id. (O'Malley, J., concurring).
283. Id. (Bryson, Gajarsa, Dyk, & Prost, JJ., dissenting).
284. Id at 24; id. at 1-2 (dissenting) ("There is broad consensus that the law of inequitable
conduct is in an unsatisfactory state and needs adjustment.").
285. Id. at 22 (citing Kimberly-Clark Corp. v. Johnson & Johnson, 745 F.2d 1437, 1454
(Fed. Cir. 1984)).
286. Id. at 23 (citing Burlington Indus., Inc. v. Dayco Corp., 849 F.2d 1418 (Fed. Cir.
1988)); id. at 2 (dissenting).
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reputable lawyers on the slenderest grounds .
Additionally,
inequitable conduct, according to the court, also plagued the entire
patent system by "casting the shadow of a hangman's noose" on patent
prosecutors,2 8 8 thereby resulting in PTO examiners being buried "with a
deluge of prior art references, most of which have marginal value[,]" 289
which, in turn, "strain[ed] the agency's examining resources and
directly contribute[d] to the backlog" at the USPTO.2 9 0
1. What Therasense Did Not Change
In addressing these concerns, the court reaffirmed that "inequitable
conduct regarding any single claim renders the entire patent
unenforceable." 29 1 Thus, the court affirmed the vitality of the doctrine
of infectious unenforceability, where the taint of a single patent claim
would infect the entire patent. Furthermore, the court reinforced the
concept that "a finding of inequitable conduct can spread from a single
patent to render unenforceable other related patents and applications in
the same technology family." 292 Thus, "a finding of inequitable conduct
may endanger a substantial portion of a company's patent portfolio." 293
In short, Therasense left unscathed the doctrine of infectious
unenforceability.
In addition to leaving the doctrine of infectious unenforceability
unchanged, the court also confirmed that "indirect and circumstantial
evidence" may be used to infer intent; this is because "direct evidence
of deceptive intent is rare." 294 Thus, while the evidentiary burden of
"clear and convincing evidence" was still required,2 9 5 that evidentiary
burden could be met with indirect and circumstantial evidence.
2. The Points on which All Members of the En Banc Court Agreed
Prior to Therasense, various panels of the Court of Appeals for the
Federal Circuit had spawned opinions that created many uncertainties,
including: (a) what standard of intent should be applied; (b) what
standard of materiality should be applied; and (c) whether there should
287. Id.
288. Id. at 23.
289. Id.; id at 2 (dissenting).
290. Id. at 24.
291. Id. at 21 (citing Kingsdown Med. Consultants, Ltd. v. Hollister, Inc., 863 F.2d 867,
877 (Fed. Cir. 1988)); id. at 2 (dissenting).
292. Id. at 22 (citing Consol. Aluminum Corp. v. Foseco Int'l, Ltd., 910 F.2d 804, 808-12
(Fed. Cir. 1990)).
293. Id.
294. Id. at 25.
295. Id. at 19.
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be a "sliding scale" under which a strong showing of either materiality
or intent should be able to make up for a weaker showing on the other
element. 296 In deciding Therasense, the en banc court unanimously
agreed on two of these points.
First, the en banc court unanimously agreed that intent and
materiality were two separate requirements,2 97 both of which required
proof by clear and convincing evidence. 2 98 The court stated that
employing a "sliding scale" was inapproriate, and that intent may not
be inferred merely from materiality. 9 Despite this, the court
specifically noted that the degree of materiality, while not to be used as
a proxy for intent, could be considered as relevant to the issue of

intent.
Second, in establishing a proper standard for intent, all of the
members of the en banc court unanimously agreed that specific intent
was required.3 0 1 Specifically, while the court stated that intent may be
inferred from indirect or circumstantial evidence,3 0 2 it "tighten[ed] the
standard" 303 by requiring that the indirect or circumstantial evidence is
the "single most reasonable inference able to be drawn from the
evidence." 304 This proof of intent could be shown by clear and
296. Id. at 2.
297. Id. at 25 ("Intent and materiality are separate requirements"); id at 3 (concurring)
("intent to deceive and materiality must be found separately"); id. at 2-3 ("a party invoking the
defense of inequitable conduct should be required to prove both specific intent and materiality
by clear and convincing evidence. . . .").
298. Id. at 19 ("accused infringer must prove both elements ... by clear and convincing
evidence"); id. at 2-3 (dissenting) ("required to prove both specific intent and materiality by
clear and convincing evidence. . . .").
299. Id. at 25 ("court should not use a 'sliding scale"'); id. at 3 (concurring) ("courts may
not employ a 'sliding scale'); id. at 3 ("there should be no 'sliding scale').
300. Id. n. 1 (concurring) ("the majority does not hold that it is impermissible for a court to
consider the level of materiality as circumstantial evidence in its intent analysis").
It is important to distinguish between relaxing the required proof of intent if the
proof of materiality is strong, which is impermissible, as opposed to
considering the degree of materiality as relevant to the issue of intent, which is
appropriate, particularly given that direct evidence of intent, such as an
admission of deceptive purpose, is seldom available.
Id.
301. Id. at 24 ("accused infringer must prove that the patentee acted with the specific intent
to deceive"); id. at 2-3 (concurring) ("a district court must find that the conduct at issue is of
sufficient culpability to require a finding of intent to deceive"); id. at 2-3 (dissenting) ("proof of
inequitable conduct should require a showing of specific intent to deceive").
302. Id. at 24; id. at 3 (concurring).
303. Id. at 24.
304. Id. at 25 (citing Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537, F.3d 1357,
1366 (Fed. Cir. 2008)); id. at 3 (concurring).
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convincing evidence that: (a) the applicant knew the information; (b)
the applicant knew that the information was material; and (c the
applicant made a deliberate decision to withhold the information.
As to the materiality element, the en banc court was sharply
divided.30 6 It is to this division that we now turn our attention.
3. The "But For" Standard for Materiality as Voiced by the Majority
The Therasense majority adopted a "but for" materiality standard in
which information is but for material if the PTO would not have
allowed a claim had it been aware of the undisclosed information.307
Axiomatically, the court held that if a claim is properly invalidated in
district court based on deliberately withheld information, then that
information is necessarily material because a finding of invalidity in a
district court requires clear and convincing evidence a higher
evidentiary burden than that used in prosecution at the PTO.Is
In addition to creating the "but for" standard of materiality, the
majority further created an exception where "the general rule requiring
but-for materiality" would not apply "in cases of affirmative egregious
misconduct." 309 In creating this exception, the majority specifically
noted that the submission of a false affidavit was necessarily material,3
and that finding inequitable conduct in cases where an unmistakably
false affidavit had been filed would allow courts to flexibly capture
extraordinary circumstances in accordance with the principles of
305. Id. at 24.
306. Infra Part IV.B.3-5.
307. Therasense, Inc. v. Becton, Dickenson & Co., Slip Op. Docket No. 2008-1511, -1512,
-1513, -1514, -1595 (Fed. Cir., decided May 25, 2011) (Rader, C.J.). We note that the court
specifically speaks of "undisclosed reference" or "undisclosed prior art" in the context of
"but for" materiality. However, in this Article, we extend this generally to all undisclosed
information because it is apparent that other information can also be "but for" material if that
information would form the basis for invalidating a patent claim. For example, prior-use
information is "but for" material if the USPTO would have rejected a patent claim based on the
prior-use information (see Keystone Driller Co. v. Gen. Excavator Co., 290 U.S. 240 (1933)),
fabricated dates are "but for" material if the USPTO would not have allowed a patent claim in
view of those dates (see Precision Instruments Mfg. Co. v. Hartford-Empire Co., 322 U.S. 238
(1944)). Specifically, MPEP § 2001.06(c) refers to "any assertion that is made during litigation
which is contradictory to assertions made to the examiner." Clearly, while these are not
"references" as noted in Therasense, they are information material to patentability as defined by
the USPTO.
308. Id. at 28.
309. Id. at 29.
310. Id. ("there is no room to argue that submission of false affidavits is not material")
(citing Rohm & Haas Co. v. Crystal Chem. Co., 722 F.2d 1556, 1571 (Fed. Cir. 1983)); id.
("affidavits are inherently material") (citing Refac Int'l, Ltd. v. Lotus Dev. Corp., 81 F.3d 1576,
1583 (Fed. Cir. 1996)).
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equity. 3 11
4. The Rule 56 Standard for Materiality as Voiced by the Dissent
Unlike the majority, the Therasense Dissent argued that the proper
standard for materiality should be governed by the PTO's disclosure
rules 3 12 set forth in 37 C.F.R. § 1.56 (Rule 56).313 The Therasense
dissent noted several reasons why Rule 56 should form the basis for
materiality. First, the court had consistently held that the PTO's Rule 56
sets the proper baseline for determining materiality. 3 14 Second, Rule 56
most closely aligns with how one ought to conduct business with the
PTO, 15 and the PTO has specifically asked the court to adopt the
Rule 56 standard for materiality. 3 16 Third, the "but for" standard is
inconsistent with the duty that the Supreme Court has described.
Fourth, the materiality standard of Rule 56 is consistent with the
materialit standard that can be found in a plethora of other legal
contexts.
Fifth and most compellingly, the majority's "but for"
standard of materiality would reward deceit because the patent would
only be lost if the claims would otherwise be held invalid.3 1 9 Thus, the
311. Id. at 30.
312. Id. at 6 (dissenting) ("I would adhere to the materiality standard set forth in the PTO's
disclosure rule. . .
313. Id. at 3.
314. Id. at 5.
315. Id. at 4.
316. Id. at 8, 17 & 27 ("As the PTO persuasively argues in its amicus brief, the 'but for'
standard for materiality is too restrictive to serve the purposes that the doctrine of inequitable
conduct was designed to promote.").
317. Id. at 10-17.
318. Id. at 27-31.
319. Id. at 9-10.
If a failure to disclose constitutes inequitable conduct only when a proper
disclosure would result in rejection of a claim, there will be little incentive for
applicants to be candid with the PTO, because in most instances the sanction of
inequitable conduct will apply only if the claims that issue are invalid anway.
Even if the nondisclosure or misleading disclosure is later discovered, under the
majority's rule the applicant is no worse off, as the patent will be lost only if the
claims would otherwise be held invalid. So there is little to lose by following a
course of deceit.
Given the large stakes sometimes at issue in patent prosecutions, a regime that
ensures that a dishonest but potentially profitable course of action can be
pursued with essentially no marginal added risk is an unwise regime no matter
how virtuous the subjects.
Id.
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Therasense dissent would presently define materiality as information
that "establishes a prima facie case of unpatentability" 20 or "refutes or
is inconsistent with a position
the applicant takes before the PTO with
32 1
respect to patentability."
5. The Flexible, Equitable Standard for Materiality as
Voiced by the Concurrence
The Therasense concurrence posits a more flexible approach,
reasoning that "both the majority and dissent strain too hard to impose
hard and fast rules."32 2 According to the Therasense concurrence,
conduct would be
deemed material where: (1) but for the conduct (whether it be in
the form of an affirmative act or intentional non-disclosure), the
patent would not have issued (as Chief Judge Rader explains that
concept in the majority opinion); (2) the conduct constitutes a
false or misleading representation of fact (rendered so either
because the statement is false on its face or information is
omitted which, if known, would render the representation false or
misleading; or (3) the district court finds that the behavior is so
offensive that the court is left with a firm conviction that the
integrity of the PTO process as to the application at issue was
wholly undermined.32
In short, the Therasense concurrence finds that the Therasense
dissent is overly vague and broad and leaves room for findings of
inequitable conduct in circumstances that are not sufficiently
egregious.324 Conversely, the Therasense concurrence finds the
Therasense majority's "but for" test to be
too restrictive, allowing for
325
misconduct that is sufficiently egregious.

V. THE BR CA

LAWSUIT

Identifying all human genes andproteins will have great
medical significance.326
320. Id. at 3.
321. Id.
322. Id. at 3 (concurring).
323. Id. at 9.
324. Id.
325. Id. at 10.
326. Daniel Nathans, Interim President, Johns Hopkins University, Life Science in Japan
Seen from Abroad, Science in Japan: Present and Future, Japan Society for the Promotion of
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We now turn to the BRCA Lawsuit and analyze the portions of the
proceedings that are relevant to our inquiry on inequitable conduct. In
particular, we examine the plaintiffs' pleadings, affidavits, motions, and
legal memoranda (collectively "filings") in the BRCA Lawsuit for their
statements and arguments that may raise the specter of inequitable
conduct under the various Therasense opinions.32 7 In particular, we look
to statements and arguments that can be imputed to the following
plaintiffs: Haig Kazazian, 328 Arupa Ganguly, 329 Wendy Chung, 330 Harry

Ostrer, 33 1 David Ledbetter, 332 Stephen Warren, 333 Ellen Matloff,334 or
Elsa Reich 335 (collectively referred to as "University plaintiffs" or
"University employees").
A. Facts andArguments Advanced by the University Employees
In reviewing the statements of the University employees, we look
specifically to the Complaint, 336 the memorandum 337 and statement of
material facts33 8 supporting plaintiffs' motion for summary judgment 3 39
(as filed in the Southern District of New York), and the arguments
advanced in the appellee's brief3 40 before the Court of Appeals for the
Federal Circuit. Because the University employees are named plaintiffs
in the BRCA Lawsuit, it is axiomatic that the plaintiffs' statements and
arguments necessarily reflect the position of these University
employees.
1. University Employees' Statements in the Complaint
In the Complaint originally filed, the University employees
Science, Wash., D.C., Feb. 7, 1996.
327. Namely, the majority, concurrence, and dissent in Therasense.
328. From the University of Pennsylvania School of Medicine. See BRCA Lawsuit, No.
09-4515-RWS (S.D.N.Y., Filed May 12, 2009), Complaint 11.
329. From the University of Pennsylvania. See id. 12.
330. From Columbia University. See id. 13.
331. From New York University School of Medicine. See id. 14.
332. From Emory University School of Medicine. See id. 15.
333. From Emory University. See id. 1 16.
334. From Yale Cancer Genetic Counseling Program. See id. 1 17.
335. From New York University. See id. 18.
336. Id. Doc. No. 1, Complaint.
337. Id. Doc. No. 62, Plaintifs' Memorandum of Law In Support of Motion for Summary
Judgment.
338. Id. Doc. No. 63, PlaintiffsRule 56.1 Statement ofMaterialFacts.
339. Id. Doc. No. 61, Plaintiff'sMotion for Summary Judgment.
340. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, Appeal Docket
No. 2010-1406, Brieffor the Appellees (filed on Nov. 30, 2010).
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collectively alleged that
[t]he patenting of human genes, the concept of looking at or
comparing human genes, and correlations found in nature
between certain genes and an increased risk of breast and/or
ovarian cancer violates long established legal principles that
prohibit the patenting of laws of nature, products of nature, and
abstract ideas.3 4 '
Additionally, the University employees alleged that "genes are existing
products of nature, naturally occurring within the human body" 342 and
that Myriad simply "located them in nature and merely described their
informational content as it exists and functions in nature." 343
The University employees also alleged that "Myriad did not invent,
create or in any way construct the differences found when genes are
compared or the correlations between certain mutations and an
increased risk of breast and/or ovarian cancer. Nature did that. Myriad
identified nature's laws." 344 Consequently, simply "[riemoving a
product of nature from its natural location does not make it any less a
product of nature." 345 In attacking the method claims, the University
employees allege that "[w]hat is patented is the abstract idea that nature
has made the two forms of the ... genes different." 346
The thrust of the University employees' position is that the "genes,
their effects, and the correlations between the genes and disease were
created by nature and exist in nature." 347 Thus, being "products of
nature, laws of nature and/or natural phenomena, and abstract ideas or
basic human knowledge or thought, the challenged claims are
invalid ...

348

2. University Employees' Position in the Plaintiffs' Statements of
Material Facts and Legal Memoranda in the Southern District of
New York
These factual allegations in the Complaint are reinforced by the
position that the University employees take in their dispositive motion.
Specifically, the University employees argue in their legal
341.
342.
343.
344.
345.
346.
347.
348.

BRCA Lawsuit, Complaint
Id. 46.
Id.
Id. 147.
Id. 51.
Id. 1 72-75.
Id. 83.
Id. 102-03.

4.
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memoranda 349 and statement of material facts35 0 that patent claims
relating to isolated sequences are products of nature and, hence, not
patentable subject matter.
For example, in their statement of material facts, the plaintiffs repeat
their factual allegation from the Complaint, namely, that "[g]enes and
human genetic sequences are not inventions of humans[4" and that
"[t]hey are naturally occurring and are products of nature."' Also, the
plaintiffs state that the "information contained in the genetic sequence is
a product of nature[,]" 352 which does not change during the process of
sequencing. 353 Furthermore, the plaintiffs aver that genetic alterations
are caused by nature,35 4 as are the significance of these alterations,3 5 5
along with their correlation to any diseased state. 356
Additionally, in their arguments, the plaintiffs allege that
[t]he patenting of human genes, the concept of looking at or
comparing human genes, and correlations found in nature
between mutated genes and an increased risk of breast and/or
ovarian cancer violates long-established Supreme Court
precedent that prohibits the patenting of laws of nature, physical
phenomena, and abstract ideas. 357
In short, the plaintiffs ar ue that "[a]ll of these claims embody products
and laws of nature[,]" 3 thereby making them non-statutory subject
matter. 359 As to the method claims, the plaintiffs argue that the
349. Id. Doc. No. 62, Plaintis' Memorandum of Law In Support of Motion for Summary
Judgment.
350. Id. Doc. No. 63, Plaintif'sRule 56.1 Statement ofMaterialFacts.
351. Id. 1 40 (citing to the declarations of Sulston 10; Ostrer 14; Chung 125; Mason 1
33; Ledbetter 27 & Leonard 15); see also id. 93 & 94.
352. Id. 49 (citing D. Sulston $ 17).
353. Id. 59 & 96 (citing D. Sulston 27; D. Chung 10; D. Mason 32-33).
354. Id. %60 & 99 (citing D. Sulston 27; D. Chung 10).
355. Id. 72 (citing D. Chung, $ 10; D. Mason 20; D. Sulston 27; D. Ledbetter 26).
356. Id. 1 73 (citing D. Mason 32; id. Doc. No. 63, Plaintffs' Rule 56.1 Statement of
MaterialFacts 81 (citing D. Mason 20)).
357. Id. Doc. No. 62, Plaintifs' Memorandum of Law In Support of Motion for Summary
Judgment, at 19.
358. Id. at 20.
359. See, e.g., id. at 20-21 ("Supreme Court precedent establishes that merely extracting,
purifying, or changing a natural product does not render that product patent-eligible, unless a
fundamentally new product is created. Because the composition claims patent genes that simply
have been removed from other cellular materials or genes whose non-coding sections have been
removed, this case law mandates the invalidation of these claims."); id. at 22 ("gene sequences
and mutations are neither machine nor manufacture"); id. at 25-26 ("Genes are products of
nature and sequencing genes does not produce something with a new function. Indeed,
sequencing is designed solely to reveal the functions of the gene dictated by nature"); id. at 30
("The fact that a BRCA2 alteration 'indicates a predisposition to said cancer' is a law of nature
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processes are abstract mental processes.360 All of these factual
statements and legal arguments can be imputed to the University
employees, since they are named plaintiffs in the BRCA Lawsuit.
3. University Employees' Position the Brief for Appellees at the
Court of Appeals for the Federal Circuit
Consistent with their position in their Complaint and their
dispositive motion, the plaintiffs-appellees argue the same points to the
Court of Appeals for the Federal Circuit, namely, that the claims are
prohibited 3 because: (a) the claims for the isolated sequences are
directed to products of nature; 362 and (b) the method claims are merely
or scientific principle, not a relationship invented by the patent holder"); id. at 36 ("genes exist
in nature as do the mutations on those genes"; "[t]he sequence of those genes exists in nature";
"[t]he functions of those genes exist in nature"; "[t]he effects of alterations in those genes are
created by nature").
360. Id. at 29 ("Because this patent claim is directed to an unpatentable abstract mental
process, it cannot satisfy section 101"); id. at 30 ("the claims on comparing genes patent abstract
thought: comparing two gene sequences for naturally-occurring differences. The similarities or
differences between the two compared genes were not created by the inventor. . .").
361. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, Appeal Docket
No. 2010-1406, Brieffor the Appellees (filed on Nov. 30, 2010), at 37 ("37: The patenting of
human genes violates long-established Supreme Court precedent that prohibits the patenting of
laws of nature, natural phenomena, products of nature, and abstract ideas.").
362. Id. at 6.
Every human body contains genes that determine, in part, the structure and
functions of the body. Through naturally-occurring processes in the body,
genes create proteins (or polypeptides), and those proteins do the work of the
body. Genes vary from one individual to another. Genetic alterations can be
inherited or can occur after birth, but in both instances they come about
naturally. Alterations can appear to be unimportant, correlate with an increased
risk of disease or disorder ("mutations"), or have unknown significance
("variant of unknown significance"). The significance of the alteration is
created entirely by nature.
Id.; id. at 7 ("The structure, function, and sequence of the nucleotides are created entirely by
nature."); id. at 9 ("Each of the claims defines isolated DNA according to how DNA functions
in the body."); id. at 14 ("14: Myriad did not create the structure, functions, or sequence of the
nucleotides that constitute the BRCA1/2 genes, the structure or function of the BRCAl/2 genes,
or the significance of the sequence for breast and/or ovarian cancer. Nature did."); id. at 22.
22: "Isolated DNA" is DNA that has simply been isolated from other cellular
components, and the information it embodies - the nucleotide sequence that
contains the instructions for the functioning of the body's cells - remains the
same. Thus, isolated DNA has neither a "distinctive name, character, and use,"
or "markedly different characteristics from any found in nature"; it is "nature's
handiwork."
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abstract ideas. 363 In other words, the University employees in the BRCA
Lawsuit maintained a consistent position from their filing of the
Complaint, through their statements and arguments for summary
judgment, and through their arguments on appeal. Thus, one can only
conclude that notice of the University employees' position was
adequately public as of the date of the Complaint.
B. Affidavits Filedby Several University Employees
In addition to the arguments and statements of facts set forth in
plaintiffs' filings, at least three University employees-Drs. Wendy K.
Chung, Harry Ostrer, and David H. Ledbetter-filed sworn affidavits in
the Southern District of New York expressly stating that "genes are
products of nature and not inventions of man." 364 Notably, Drs. Chung
and Ledbetter have patents with claims that are analogous to the ones
that they challenge in the Southern District of New York.36 5 In short,
Drs. Chung and Ledbetter filed inventor declarations in the USPTO,
indicating that their own isolated-sequence-related patents were
patentable, yet they filed affidavits in the BRCA Lawsuit indicating that
Myriad's isolated-sequence-related patents were not patentable.
C. The District Court'sDisposition of the Case
Setting aside all issues relating to jurisdiction and justiciability, 366
Id.; id. at 39 ("Once Supreme Court precedent is applied to the nine challenged patent claims
over 'isolated DNA,' they do not survive section 101 because they cover natural phenomena
and products of nature"); id. ("Isolated DNA Is Not Patentable Subject Matter Under Supreme
Court Precedent.").
363. Id. at 12 ("Myriad's method claims cover the abstract idea of looking at DNA
sequences and thinking about their significance. As such, they do not constitute patentable
subject matter."); id. at 59.
59: Claim 20 of the '282 patents the abstract idea of comparing growth rates of
two cells, which are dictated by nature, and preempts a basic scientific principle
extended to the BRCAl gene context: that a slower rate of cell growth in the
presence of a compound may indicate that the compound is a cancer
therapeutic.
Id.
364. BRCA Lawsuit, Civil Action No. 09-4515-RWS, Doc. Nos. 40 (Declaration of Wendy
K. Chung (Columbia)), 47 (Declaration of Harry Ostrer (NYU)), 48 (Declaration of David H.
Ledbetter (Emory)), 78 (Chung), 85 (Ostrer) & 86 (Ledbetter).
365. U.S. Patent No. 7,339,028 (Chung); U.S. Patent No. 6,143,504 (Ledbetter).
366. Insofar as issues relating to jurisdiction and justiciability (such as standing) are
inapplicable to our substantive analysis on inequitable conduct, we focus only on the court
rulings that relate to the isolated sequences and corresponding methods. We do this for both the
opinion from the Southern District of New York as well as the opinion from the Court of
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the Southern District of New York invalidated all of the disputed patent
claims in the BRCA Lawsuit.367 In a lengthy order penned by Judge
Robert Sweet, the Southern District of New York dissected the
following categories of patent claims: (a) isolated sequences;368
(b) method claims for analyzing and comparing sequences; 369 and
(c) method claims for comparing growth rates. 3o
1. Isolated Sequences
With reference to the isolated sequences, Judge Sweet found that the
isolated sequences were not "markedly different" from the native
sequences because the "overriding importance of DNA's nucleotide
sequence to both its natural biological function as well as the utility
associated with DNA in its isolated form" was no different between the
sequences' native state and isolated state.3 71 Due to the informational
congruity between isolated sequences and native sequences, Judge
Sweet reasoned that isolated sequences were not "sufficiently distinct in
its fundamental characteristics from natural phenomena to possess the
required distinctive name, character, and use." 372 In other words,
because so much of the isolated sequences were similar to their native
counterparts, the isolated sequences were not "markedly different" from
the native sequences as they exist in nature, and thus failed under 35
U.S.C. § 101.
2. Method Claims on Analyzing and Comparing Sequences
Turning to the method claims, Judge Sweet separated them into two
distinct groups: (a) methods for analyzing and comparing sequences;
and (b) methods for comparing growth rates. In analyzing both of these
groups of claims, Judge Sweet relied heavily on In re Bilski,3 74 in which
the Court of Appeals for the Federal Circuit had limited the analysis for
patentable subject matter to a machine-or-transformation test. 375
With reference to the method claims for analyzing and comparing
sequences, Judge Sweet noted that Myriad's patent claims were
"directed only to the abstract mental processes of 'comparing' or
Appeals for the Federal Circuit.
367. BRCA Lawsuit, Order, Doc. No. 255 (S.D.N.Y., Mar. 29, 2010).
368. Id. at 121-35.
369. Id. at 137-47.
370. Id. at 147-49.
371. Id. at 125.
372. Id. at 127 (internal quotations and brackets omitted).
373. Id. at 135.
374. 545 F.3d 943 (Fed. Cir. 2008) (en banc).
375. BRCA Lawsuit, Order, Doc. No. 255, at 136.

2012]1

ASSOCIATION OF MOLECULAR PATHOLOGY MEETS THERASENSE

45

'analyzing' gene sequences."376 Rejecting Myriad's contention that the
method steps necessarily included a transformation, insofar as they
required extraction, Judge Sweet relied heavily on the claim language
itself to determine that the patent claim, as written, did not require any
transformative steps.3 77 Furthermore, assuming arguendo that the
method claims included the transformative steps of isolating and
sequencing the sequence, Judge Sweet nevertheless found that those
steps were not "central to the purpose of the claimed process."378 As
such, the method claims on comparing isolated sequences was held
invalid under 35 U.S.C. § 101.
3. Method Claims on Comparing Growth Rates
Lastly, Judge Sweet turned his attention to the method claims on
comparing growth rates of cells in the presence or absence of a potential
cancer therapeutic. 379 Characterizing "the essence of the claim, 380 as
being a basic scientific principle, Judge Sweet invalidated the method
claim for comparing growth rates as simply a mental process,
unpatentable under 35 U.S.C. § 10 11
D. The Court of Appealsfor the FederalCircuit
Having all of its claims invalidated, Defendants appealed Judge
Sweet's decision to the Court of Appeals for the Federal Circuit. The
appellate court issued three separate opinions by each member of the
three-judge panel.3 82 Although the appellate court addressed the issues
relating to jurisdiction and justiciability, 383 we do not discuss those
aspects of the case in detail, as they are only peripherally related to our
topic.
1. Judge Lourie's Majority Opinion for the Court
The majority held: (a) Myriad's isolated sequences were patentable
subject matter; (b) Myriad's methods on comparing or analyzing gene
376. Id. at 141.
377. Id. at 144-45.
378. Id. at 145.
379. Id. at 147-49.
380. Id. at 149.
381. Id.
382. Ass'n for Molecular Pathology v. Myriad, Docket No. 2010-1406 (Fed. Cir., decided
July 29, 2011) (Lourie Opinion); id. (Moore, J., concurring-in-part) (Moore Concurrence); id.
(Bryson, J., concurring-in-part and dissenting-in-part) (Bryson Dissent).
383. Id. at 24-35 (Lourie Opinion); id. at 2 (Moore, J., concurring); id. at 2 (Bryson, J.,
dissenting).
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sequences were not patentable subject matter; and (c) Myriad's method
of screening potential therapeutics via changes in cell growth was
patentable subject matter.3 84
The court first addressed the subject-matter eligibility of isolated
DNA.3 85 Specifically, the court noted: (a) all of the parties seemed to
agree that isolated DNA is a composition of matter; and (b) the only
disagreement was whether and to what degree the DNA molecule fell
within the exception for products of nature. 3 86 With this
characterization, the court stated that there was "a line between
compositions that, even if combined or altered in a manner not found in
nature, have similar characteristics as in nature, and compositions that
human intervention has given 'markedly different,' or 'distinctive,'
characteristics." 387 Insofar as Myriad's isolated sequences "are
markedly different - have a distinctive chemical identity and nature from molecules that exist in nature[,]" 388 those sequences fall outside of
the products-of-nature exception.
The court further noted that "patent eligibility of an isolated DNA is
not negated because it has similar informational properties to a
different, more complex natural material that embodies it." 389
Contrasting isolated sequences to merely "[s]napping a leaf from a
tree[,]" 390 the court noted that while leaf-removing simply involved a
physical separation 391 isolated sequences involved "creating a new
chemical entity[.]"32 Additionally, the court indicated that any change
in subject-matter eligibility "must come not from the courts, but from
Congress." 393
Next, turning its attention to the method claims, the court separated
this group of patent claims into two distinct categories: (a) methods of
("comparing-or-analyzing
or analyzing sequences
comparin
claims"); 94 and (b) method of screening potential cancer therapeutics
("screening claim"). 39 5
With reference to the comparing-or-analyzing claims, the court
determined that these patent claims fell "outside the scope of § 101

384.
385.
386.
387.
388.

Id. at 54 (Lourie Opinion).
Id. at 37-48.
Id. at 39.
Id. at 41.
Id.

389. Id. at 44.

390.
391.
392.
393.
394.
395.

Id. at 47.
Id.
Id.
Id. at 48.
Id. at 49-53.
Id. at 53-54.
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because they claim only abstract mental processes." 396 The court noted
that the claimed step was the process itself, and not merely a part of a
process. 39 7 Because the method steps did not include any additional
limitations, such as isolating the genes from a blood sample or
sequencing the genes, the process did not contain anything
transformative.3 98 Thus, the court concluded that the claims were
"directed to the abstract mental process[,]" 399 which failed as "a patent
eligible process under § 101."40
With reference to the screening claim, the court found that the claim
included "an inherently transformative step involving the manipulation
of the cells and their growth medium[,]"401 thereby satisfying
section 101. Furthermore, the court held that the process was
sufficiently narrow so that it did "not preempt all usesA0 2 and presented
"functional and palpable applications in the field of biotechnology." 403
2. Judge Moore's Concurring Opinion
In a concurring opinion, Judge Moore agreed with the majority, but
wrote separately because she had different reasons for allowing isolated
sequences to be patent eligible under section 101.404 Essentially, Judge
Moore: (a) agreed with both the holding and the reasoning for all of the
method claims; and (b) agreed with the holding for the isolatedsequence claims; but (c) disagreed for why isolated-sequence claims
should be considered patentable subject matter under section 101.
In analogizing the DNA molecule to any other polymer comprising
monomer units, Judge Moore noted that "a fragment of a DNA
sequence has different properties than the parent molecule from which it
is derived." 4 05 For example, "it is impossible to find the isolated T-C
structure in the A-T-C-G-T molecule."40 6 In other words, "just because
the same series of letters appears in both the chromosome and the
isolated DNA sequences does not mean that they are the same
molecule."4 0 7 Under this backdrop, Judge Moore analyzed two separate
types of isolated sequences: (a) entirely manmade sequences, such as
396.
397.
398.
399.
400.
401.
402.
403.
404.
405.
406.
407.

Id. at 50 (Lourie Opinion).
Id. at 50-51 (Lourie Opinion).
Id. at 52 (Lourie Opinion).
Id. at 53 (Lourie Opinion).
Id.
Id.
Id. (citingPrometheus, 628 F.3d at 1355).
Id.
Id. at 2 (Moore, J., concurring).
Id. at 9.
Id.
Id. at 10.
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cDNA; and (b) isolated sequences that have the same pattern as those
sequences found in nature.
Judge Moore noted that the entirely manmade types of sequences
had "a distinctive name, character, and use, with markedly different
chemical characteristics from either the naturally occurring RNA or any
continuous DNA sequence found on the chromosome."4 0 Adopting the
same reasoning as the majority for wholly manmade sequences, Judge
Moore thus "decline[d] to extend the laws of nature exception to reach
entirely manmade sequences of isolated DNA, even if those sequences
are inspired by a natural template." 409 With reference to isolated
sequences that have the same pattern as naturally-occurring sequences,
Judge Moore first noted that the use of these isolated sequences, such as
for diagnostic testing, was "clearly an enlargement of the range of
utility as compared to nature." 410 Insofar as "the body does not naturally
engage in this type of testing[,]"411 these isolated sequences do "not
serve the ends nature originally provided[,]"41 2 and "simply cannot be
used in the same way" as it is used in nature.4 13
Judge Moore also joined the majority because "leaving intact the
settled expectations of property owners [was] particularly important in
light of the large number of property rights involved, both to isolated
DNA and to purified natural products generally."4 14 Because "more than
a century of precedent and Patent Office Practice" 4 15 would be
overturned if the court were to hold otherwise and because a contrary
conclusion would "call into question the validity of an unknown number
of patents and claims and upsetp the settled expectations of some of our
most innovative industries[,]' 4 Judge Moore was unwilling to "punish
those inquisitive enough to investigate, isolate, and patent" isolated
human DNA. 4 1 7
3. Judge Bryson's Dissenting Opinion
Judge Bryson concurred in the court's judgment regarding (a) the
cDNA claims (i.e., purely manmade sequences); and (b) the
patentability of the method claims.4 18 However, Judge Bryson
408.
409.
410.
411.

Id. at 14.
Id.
Id. at 16 (internal quotations and ellipses omitted) (citing Funk Bros. 333 U.S. at 131).
Id.

412. Id.
413. Id.
414.
415.
416.
417.
418.

Id. at 21.
Id. at 25.
Id.
Id. at 31.
Id. at 2 (Bryson, J., dissenting).
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concluded that isolated sequences with the same pattern as naturallyoccurring sequences were not patent eligible under section 101.419 Like
Judge Moore's concurrence, Judge Bryson's dissent categorizes the
isolated sequences into different categories, namely: (a) isolated
sequences; (b) manmade sequences created in a laboratory, such as
cDNA; and (c) sequences of fragments.4 2 0
For convenience, we take Judge Bryson's position out-of-order,
beginning with manmade sequences, such as cDNA. Like both the
majority and concurring opinions, Judge Bryson agreed that these types
of sequences "cannot be isolated from nature, but instead must be
created in the laboratory."4 2 1 As such, he concluded that cDNA and
other laboratory-created sequences were patentable subject matter under
section 101.422
With reference to isolating genes, Judge Bryson likened the process
to extracting minerals or cutting plants from their natural settings, and
concluded that merely isolating genes from their surroundings should
not make them patentable. 423 Additionally, Judge Bryson distinguished
extracting genes from crafting a baseball bat from an ash tree, noting
that the bat "necessarily changes the nature, form, and use of the ash
tree" 424 while genes are extracted "along lines defined by nature so as to
preserve the structure and function that the gene possessed in its natural
environment."425 In other words, because "each gene must function in
the same manner in the laboratory as it does in the human body" 42 6 and
because "that identity of function in the isolated gene is the key to its
value[,]" 427 the mere fact of isolation would be insufficient to confer
subject-matter eligibility. Lastly, turning to short sequences, Judge
Bryson advanced two separate arguments for denying patentability.
419. Id. at 3 ("We are therefore required to decide whether the process of isolating genetic
material from a human DNA molecule makes the isolated genetic material a patentable
invention. The court concludes that it does; I conclude that it does not.").
420. Id. at 4.
421. Id at 14.
422. Id.
423. Id. at 6.
And the process of extracting minerals, or taking cuttings from wild plants, like
the process of isolating genetic material, can result in some physical or
chemical changes to the natural substance. But such changes do not make
extracted minerals or plant cuttings patentable, and they should not have that
effect for isolated genes.
Id.
424.
425.
426.
427.

Id at 11.
Id
Id at 13.
Id.
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First, a claim for a very short sequence would be so broad that it would
cover "products of nature . .. and portions of other genes" 428 and that
the claim's "validity [would not be] salvaged because it includes some
species that are not natural.'A 29 Second, in an argument more akin to an
over-breadth argument under 35 U.S.C. § 112,30 Judge Bryson noted
that a claim to a very short sequence would preempt almost any gene,
"even though Myriad's specification has contributed nothing to human
understanding of other genes."431 Thus, for policy reasons, such broad
claims should be patent-ineligible because they would " resent a
significant obstacle to the next generation of innovation .... '

VI. ANALYSIS

OF THE UNIVERSITY EMPLOYEES' STATEMENTS IN
VIEW OF THERASENSE

No man has a good enough memory to be a successful liar.4 33
Given the pronouncements from the Court of Appeals for the Federal
Circuit, we now analyze the statements by the University employees in
the BRCA Lawsuit to determine whether or not various patents held by
the University of Pennsylvania, Columbia University, New York
University, Yale University, and Emory University are vulnerable to
allegations of inequitable conduct. Insofar as infectious unenforceability
can be found for inequitable conduct by anyone that is substantially
related to the prosecution of a patent (i.e., inventors, attorneys, in-house
decision-makers, etc.),434 we review the conduct of both the University
employees as well as those who are employed in the technology transfer
offices for these institutions.
A. Analysis of the University Employees
We first start with the University employees who also happen to be
inventors on patents and patent applications that are directed to isolated
sequences and methods associated with isolated sequences.435 As noted
above, these University employees filed pleadings, motions, and
affidavits in the Southern District of New York stating that isolated
sequences and methods associated with isolated sequences were not
428. Id. at 15.

429. Id.
430. 35 U.S.C. § 112,
431.
432.
433.
434.
435.

1.

Myriad, Docket No. 2010-1406, at 14 (Bryson, J., dissenting).
Id. at 16.
Abraham Lincoln.
37 C.F.R. § 1.56.
See supra Part III.B.
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patentable subject matter. 436 We review those statements in view of
Therasense to determine whether or not the University employees'
issued patents and published patent applications are susceptible to
attacks for inequitable conduct.
1. Establishing Specific Intent to Deceive by the University Employees
The entire en bane court in Therasense agreed that three elements
form the specific intent to deceive: (a) knowledge of the information;
(b) knowledge of its materiality; and (c) deliberate withholding of the
information.
Thus, in order to properly analyze both intent and
materiality, we need to properly identify the information to which we
are applying our test. Essentially, the preliminary question is: what is
the information? Because the primary issue in the BRCA Lawsuit is the
subject-matter eligibility of isolated sequences, the relevant information
is any fact showing that isolated sequences are products of nature.
With the contours of our inquiry now defined, we first look to the
affidavits filed in the Southern District of New York, because
Therasense held that "affidavits are inherently material.'A3 8 First, Drs.
Chung, Ostrer, and Ledbetter filed affidavits in the BRCA Lawsuit,
swearin that "genes are products of nature and not inventions of
man."4 3 Insofar as these learned individuals are well-established in
their respective fields, it is reasonable to presume that they have always
known that "genes are products of nature and not inventions of man.' 4 0
Thus, the first prong of the Therasense intent is established for these
University employees.
Second, because Therasense held that affidavits are inherently
material,44 the statements of Drs. Chung, Ostrer, and Ledbetter are
undoubtedly material. Additionally, because Drs. Chung, Ostrer, and
Ledbetter filed this information with the court in an effort to invalidate
Myriad's gene patents, there is little doubt that Drs. Chung, Ostrer, and
Ledbetter knew that this information was material. Again, because they
likely believed all along that genes were "products of nature and not
inventions of man," 442 Drs. Chung, Ostrer, and Ledbetter were required
to disclose this fact to the USPTO in any patent application that they
436. See supra PartV.
437. Therasense, Inc. v. Becton, Dickinson & Co., Slip Op., Docket No. 2008-1511, -1512,
-1513, -1514, -1595, at 24 (Fed. Cir., decided May 25, 2011).
438. Id. at 29.
439. BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., May 12, 2009), Doc. Nos. 40, 47, 48,
78, 85 & 86.
440. Id. Doc. Nos. 40,47, 48, 78, 85 & 86.
441. Therasense, Slip Op., Docket No. 2008-1511, -1512, -1513, -1514,-1595, at 29.
442. BRCA Lawsuit,No. 4515-RWS, Doc. Nos. 40, 47, 48, 78, 85 & 86.
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filed with the USPTO, as part of their duty of candor.44 3 Lastly, given
the force with which the University employees argue that genes are not
patentable, the only reasonable inference that can be drawn is that they
deliberately chose to withhold the information from the USPTO.
We next examine the statement of material facts 444 which were filed
with the plaintiffs' motion for summary judgment. 45 In addition to the
affiants, the University employees include Haig Kazazian, Arupa
Ganguly, Stephen Warren, Ellen Matloff, and Elsa Reich. The plaintiffs,
including the University employees, unequivocally state that " enes
and
and human genetic sequences are not inventions of humans[,]'
that "[t]hey are naturally occurring and are products of nature." 447
Insofar as the plaintiffs captioned their document as their "Statement of
Material Facts," it is axiomatic that: (a) these are statements of fact; and
(b) they are material. Furthermore, since the district court, agreeing with
these statements, held that all of the patent claims were invalid under 35
U.S.C. § 101 for being directed to non-statutory subject matter,4 4 8 the
University employees' statements are necessarily material, because a
finding of invalidity in a district court requires clear and convincing
evidence, a higher evidentiary burden than that used in prosecution at
the USPTO.4 4 Insofar as the University employees admit that these are
"Statements of Material Fact," it is axiomatic that they knew that the
statements were material. Thus, their failure to disclose these facts to
the USPTO during prosecution of their own patents can only be
reasonably viewed as a deliberate withholding of the facts.
The plaintiffs' allegations in their Complaint,4 5 0 along with their
arguments to the Court of Appeals for the Federal Circuit, 45 1 only
bolsters the conclusion that the plaintiffs (including the University
employees) knew the information, knew of its materiality, and
deliberately withheld it during prosecution of their own patents. In
short, with reference to any issued patents and published patent
applications by the University employees, it appears as if the intent
prong of Therasense is met.

443. 37 C.F.R. § 1.56.
444. BRCA Lawsuit, No. 4515-RWS, Doc. No. 63.
445. Id. Doc. No. 61.
446. Id Doc. No. 63,
40, 93 & 94.
40, 93 & 94.
447. Id. Doc. No. 63,
448. Id. Doc. No. 255, at 121-49.
449. Therasense, Inc. v. Becton, Dickinson & Co., Slip Op., Docket No. 2008-1511, -1512,
-1513, -1514, -1595, at 28 (Fed. Cir., decided May 25, 2011).
450. BRCA Lawsuit, No. 4515-RWS, Doc. No. 1.
451. Id. Appeal Docket No. 2010-1406, Brieffor the Appellees (filed on Nov. 30, 2010).
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2. Unenforceability Analyzed Under the Majority Opinion's "But For"
Standard for Materiality
We now turn to the question of whether these statements by the
University employees are material. Although the "sliding scale" inquiry
is abolished,4 11 the same evidence that proves intent may also be used to
prove materiality. 453 In our analysis, the evidence of materiality
overlaps with the evidence of intent.
In analyzing materiality, we again start with the affidavits filed in the
Southern District of New York. Because Therasense held that
"affidavits are inherently material," 454 the University employees'
affidavits are material. Drs. Chung, Ostrer, and Ledbetter's statements,
which are found in their court-filed affidavits, are material.
With reference to the plaintiffs' Statement of Material Facts, 45 5
which were filed with the plaintiffs' motion for summary judgment,4 5 6
all of the plaintiffs, including the University employees, unequivocally
state that "[gjenes and human genetic sequences are not inventions of
humans[,]'
and that "[t]hey are naturally occurring and are products
of nature." 4 58 Insofar as the document is captioned "Statement of
Material Facts," it is axiomatic that: (a) these are statements of fact; and
(b) they are material. Furthermore, because the district court agreed
with these statements and held all of the claims to as being invalid under
35 U.S.C. § 101,45 9 the University employees' statements are
necessarily material because a finding of invalidity in a district court
requires clear and convincing evidence, which is a higher evidentiary
burden than that used in prosecution at the USPTO.46 0

452. Therasense, Slip Op., Docket No. 2008-1511, at 25; id. at 3 (concurring); id. at 2-3
(dissenting).
453. Id. n.1 (concurring).
As in all other legal inquiries involving multiple elements, the district court
may rely on the same items of evidence in both its materiality and intent
inquiries. A district court must, however, reach separate conclusions of intent
and materiality and may not base a finding of specific intent to deceive on
materiality alone, regardless of the level of materiality.
Id.
454. Id. at 29.
455. BRCA Lawsuit, No. 4515-RWS, Doc. No. 63.
456. Id. Doc. No. 61.
457. Id. Doc. No. 63, IN 40, 93 & 94.
458. Id. Doc. No. 63,
40, 93 & 94.
459. Id. Doc. No. 255, at 121-49.
460. Therasense, Inc. v. Becton, Dickinson & Co., Slip Op., Docket No. 2008-1511, -1512,
-1513, -1514, -1595, at 28 (Fed. Cir., decided May 25, 2011).
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Again, the plaintiffs' allegations in their Complaint, 46 1 along with
their arguments to the Court of Appeals for the Federal Circuit,4 only
bolsters the conclusion that this information (i.e., isolated sequences are
not patentable) is material. Given the evidence for both materiality and
intent, the issued patents and published patent applications, which these
University employees invented, are now susceptible to a finding of
unenforceability for inequitable conduct.
Specifically, Haig Kazazian, Arupa Ganguly, Wendy Chung, David
Ledbetter, and Stephen Warren have issued patents or ublished patent
Because they
applications that are directed to isolated sequences.
knew that isolated sequences were products of nature and that this
information was material, and because they deliberately withheld that
information from the USPTO, their patents are susceptible to the taint of
inequitable conduct.
3. Unenforceability Analyzed Under the Dissenting Opinion's Rule 56
Standard for Materiality
The standard for materiality under the Therasense dissent is much
lower than the "but for" standard which the Therasense majority
articulates. The Therasense dissent advocated for the materiality
standard as set forth in Rule 56.464 Under Rule 56, materialitz is
information that "establishes a prima facie case of unpatentability" 4 5 or
"refutes or is inconsistent with a position the applicant takes before the
PTO with respect to patentability."4 66 Given the lower standard under
Rule 56, it seems axiomatic that if the issued patents and published
patent applications are found unenforceable under the majority's "but
for" test, then they will likewise be held unenforceable under the
Rule 56 test.
With this in mind, we examine the University employees' position
under the Rule 56 standard. Specifically, the University employees took
the position that genes were products of nature, and were therefore
467
unpatentable.
That position is clearly inconsistent with the position
that the applicant took before the PTO with respect to patentability.
Thus, those statements are material. Therefore, because materiality and
intent can be shown under the Rule 56 standard, the issued patents and
published patent applications for which these University employees are
461.
462.
463.
464.
465.
466.
467.

BRCA Lawsuit, No. 4515-RWS, Doc. No. 1.
Id. Appeal Docket No. 2010-1406, Brieffor the Appellees (filed on Nov. 30, 2010).
See supra Part III.B.
Therasense Slip Op. Docket No. 2008-1511, at 3 (dissenting).
Id.
Id.
See supra Part V.
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inventors are now susceptible to a finding of unenforceability for
inequitable conduct.
4. Unenforceability Analyzed Under the Concurring Opinion's
Equitable Standard for Materiality
The Therasense concurrence posits a more flexible approach that
leaves the inequitable conduct inquiry to the sound discretion of the
court.468 Again, insofar as the flexible approach is more lenient than the
majority's "but for" standard for materiality, it seems axiomatic that a
finding of inequitable conduct under the "but for" test will likewise
result in a finding of inequitable conduct under the Therasense
concurrence's flexible approach.
Again, we begin with the affidavits filed in the Southern District of
New York. In those affidavits, Drs. Chung, Ostrer, and Ledbetter swore
that genes were products of nature and not patentable subject matter.4 69
Conversely, by filing a declaration with the USPTO, under penalty of
perjury, these University employees swore that their own inventions
were patentable subject matter. 7 o In other words, these University
employees filed contradictory sworn statements in separate tribunals,
both under penalty of perjury. Therefore, the University employees
must have committed perjury in at least one tribunal.
Under the Therasense Concurrence's flexible approach, it would be
within the court's sound discretion to find inequitable conduct in light
of the University employees' perjured statements.
5. Unenforceability Analyzed Under the Majority's Egregious
Misconduct Standard
Lastly, we examine unenforceability under the exception the
Therasense majority carved: "[T]he general rule requiring but-for
materiality" would not apply "in cases of affirmative egregious
misconduct." 4 7 1 Specifically, the majority noted that submitting a false
affidavit was necessarily material,4 7 2 and that finding inequitable
conduct in cases where an unmistakably false affidavit had been filed
468. See supra Part IV.B.5.
469. BRCA Lawsuit, No. 09-4515-RWS (S.D.N.Y., filed May 12, 2009), Doc. Nos. 40
(Declaration of Wendy K. Chung (Columbia)), 47 (Declaration of Harry Ostrer (NYU)), 48
(Declaration of David H. Ledbetter (Emory)), 78 (Chung), 85 (Ostrer) & 86 (Ledbetter).
470. See 37 C.F.R. § 1.56.
471. Therasense, Slip Op. Docket No. 2008-1511, at 29.
472. Id. at 29 ("there is no room to argue that submission of false affidavits is not
material") (citing Rohm & Haas Co. v. Crystal Chem. Co., 722 F.2d 1556, 1571 (Fed. Cir.
1983)); id. ("affidavits are inherently material") (citing Refac Int'l, Ltd. v. Lotus Dev. Corp., 81
F.3d 1576, 1583 (Fed. Cir. 1996)).
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would allow courts to flexibly capture extraordinary circumstances in
accordance with the principles of equity.4 73
As part of the patent-application process, the University employees
that have applied for patents have submitted oaths or declarations to the
USPTO, each under penalty of perjury.4 7 4 For those that have applied
for patents on isolated sequences, they have sworn that they believe that
they are the "original and first inventor(s) of the subject matter which is
claimed andfor which a patent is sought on the invention."4 75 In other
words, they swear their belief that patentable subject matter is being
claimed. Applying for patent protection on isolated sequences that the
University employees knew to be non-statutory subject matter falls
within "egregious misconduct" (as noted by the Therasense majority).
Specifically, Haig Kazazian, Arupa Ganguly, Wendy Chung, David
Ledbetter, and Stephen Warren have issued gatents or published patent
applications directed to isolated sequences.
Insofar as they knew that
isolated sequences were non-statutory subject matter, and insofar as
they filed an oath to the contrary, their patents are susceptible to the
taint of inequitable conduct.
B. Analysis of the Academic Institutions
It seems relatively straightforward to hold patents unenforceable for
inequitable conduct when an inventor files a sworn statement with the
USPTO averring that the inventor is entitled to a patent on isolated
sequences, yet files a contradictory sworn statement in a court
proceeding averring that isolated sequences are non-statutory subject
matter. However, the analysis is not so straightforward when applied to
individuals in a technology transfer office, who are "substantively
involved in the preparation or prosecution of the [patent]
application. , 77
473. Id. at 30.
474. See Form SB-01, Oath, USPTO, available at http://www.uspto.gov/web/forms/
sb0001.pdf.
I hereby declare that all statements made herein of my own knowledge are true
and that all statements made on information and belief are believed to be true;
and further that these statements were made with the knowledge that willful
false statements and the like so made are punishable by fine or imprisonment,
or both, under 18 U.S.C. 1001 and that such willful false statements may
jeopardize the validity of the application or any patent issued thereon.
Id.
475. Id. (emphasis added).
476. See supraPart III.B.
477. 37 C.F.R. § 1.56.
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1. Analysis of Materiality
We start this Part with an analysis of materiality because the
question of materiality remains the same, irrespective of whether the
information is viewed from the perspective of an inventor, an attorney,
or any other individual substantively involved in prosecuting patent
applications. In short, whether or not information is material is whollydependent on the information in relation to the patent claim. For
example, under the Therasense majority's "but for" standard for
materiality, we analyze the withheld information to see if a patent claim
would have been allowed "but for" the withheld information.47 8 Under
the Therasense Dissent's Rule 56 standard for materiality, we analyze
the withheld information to see if that information "establishes a prima
facie case of unpatentability" 479 of a particular patent claim or "refutes
or is inconsistent with a position the applicant takes before the PTO
with respect to patentability."4 8 0 Lastly, under the Therasense
concurrence's flexible approach to materiality, we analyze the
information to determine whether a misrepresentation or omission taints
a particular patent claim, such that a court can exercise its discretion to
find inequitable conduct. 48 1
Because the materiality analysis for those that are substantively
involved in prosecution is the same as the materiality analysis as it
relates to inventors, we do not reiterate that analysis here. Instead, we
refer the reader to the Parts, supra, which address materiality under all
three Therasense opinions (i.e., the majority, the dissent, and the
concurrence).
2. Establishing Specific Intent to Deceive by the Representatives of the
Academic Institutions
The en banc court unanimously agreed that proof of specific intent
could be shown by clear and convincing evidence that: (a) the
information was known; (b) the materiality of the information was
known; and (c) a deliberate decision to withhold the information was
made.48 2 Unlike proving intent for the inventors, it is slightly more
difficult to prove intent for those that are substantively involved in
prosecuting a patent application. In the context of this Article, those that
are substantively involved in prosecution are the relevant technology

478.
479.
480.
481.
482.

Therasense, Slip Op. Docket No. 2008-1511, at 27.
Id. at 3 (dissenting).
Id.
Id. at 9 (concurring).
Id. at 24.
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licensing officers at the technology transfer offices.
Specifically, the
first prong, whether or not the TLOs knew of the information, is the
weakest element. Though it is axiomatic that inventors know of their
own statements, the TLOs are one step removed from the inventors'
statements, thereby requiring an additional layer of proof. Unlike
proving the first prong (i.e., knowledge of the information itself), proof
of the second prong (i.e., knowledge of materiality) and the third prong
(i.e., deliberate nondisclosure) are relatively straightforward by
comparison. Thus, we begin with the last two prongs of intent, and then
move to the first prong.
a. Knowledge of Materiality of Information
The TLOs for the various academic institutions are experienced
individuals that mine patentable inventions and deal with patent
prosecution matters on a daily basis.4 84 As such, it is reasonable to
presume that they are able to assess the information's materiality
regarding a particular patent claim. Specifically, with reference to the
BRCA Lawsuit, the TLOs likely know that sworn statements by their
own inventors are material when those inventors state, under oath, that
isolated genes and corresponding methods are products of nature and,
therefore, not patentable subject matter.
b. Deliberate Withholding of Information
Next, when TLOs withhold information, fully knowing of the
information's materiality, there can be only one reasonable explanation,
especially given their familiarity with the patent prosecution process.
That reasonable explanation is that the information was deliberately
withheld.
Accordingly, in the context of the BRCA Lawsuit, there is only one
reasonable explanation for withholding an inventor's own sworn
statement that directly contradicts another of the inventor's own sworn
statement. Namely, that the inventor's sworn statement was deliberately
withheld from the USPTO.
c. Knowledge of the Information
Insofar as the TLOs own experience and training evidences their
knowledge of materiality and their deliberate withholding of
information, the entire intent inquiry for the TLOs hinges on the
483. Supra Part II.A.5-9.
484. Therasense, Slip Op. Docket No. 2008-1511, at 24.

20121

ASSOCIATION OF MOLECULAR PATHOLOGY MEETS THERASENSE

59

question of whether or not the TLOs knew of the information in the first
place. It is to that inquiry that we now turn.
We must ask whether: (a) the TLOs knew that their own
University's employees were plaintiffs in the BRCA Lawsuit; and (b)
the TLOs knew that their own University's employees had submitted
statements of fact that directly opposed patentability of isolated
sequences. If both of these inquiries are answered in the affirmative,
then the first prong of intent under Therasense is established.
First, the BRCA Lawsuit is one of the most-publicized cases in recent
history, having been reported in scientific magazines,4 8 5 popular news
channels, 4 86 blogs, 4 87 legal publications,488 and even making the news
page of the Association of University Technology Managers
(AUTM).4 8 9 Thus, given our presumption that the TLOs stay current on
recent developments in patent law, and given the widespread
dissemination of this case through a plethora of readily-available
information sources, the TLOs most likely knew of the BRCA Lawsuit.
Second, insofar as UPenn, Columbia, NYU, Yale, and Emory in the
aggregate filed 1,110 sequence-related patent applications during the
pendency of the BRCA Lawsuit,4 90 the TLOs that were keeping abreast
485. Eliot Marshall, Lawsuit Challenges Legal Basis for Patenting Human Genes, 324
SCIENCE 1000-1001 (May 2009); Meredith Wadman, Breast Cancer Gene Patents Judged
Invalid, Nature (Mar. 30, 2010), http://www.nature.com/news/2010/100330/full/news.2010.
160.html.
486. John Schwartz, CancerPatients Challenge the Patentingofa Gene, N.Y. TIMES (May
12, 2009), http://www.nytimes.com/2009/05/13/health/13patent.html; Nathan Koppel & Shirley
Wang, Judge Rejects Patent on Genes, WALL ST. J. (Mar. 30, 2010), http://online.wsj.com/
article/SB10001424052702303410404575152553258232416.html?mod=WSJ latestheadlines.
487. Patents on Breast Cancer Genes Ruled Invalid, YALE CANCER GENETIC COUNSELING

(Mar. 30, 2010), http://yalecancergeneticcounseling.blogspot.com/2010/03/patents-on-breastcancer-genes-ruled.html; Court: Essentially All Gene Patents are Invalid, PATENTLY-O (Mar.
30, 2010), http://www.patentlyo.com/patent/2010/03/court-essentially-all-gene-patents-areinvalid.html; Hannah Stein, DNAC: Patenting Life and the Human Genome, PROPERTY LAW
508 (Nov. 17, 2009), www.law.upenn.edu/blogs/polk/property/2009/1 1/dna-patenting-life-andthe-human-genome.html.
488. See, e.g., Alex Osterlind, Staking a Claim on the Building Blocks of Life: Human
Genetic Material within the United States Patent System, 75 Mo. L. REv. 617 (2010); Ouellette,
supra note 4; Powell & Elman, supra note 4, at 23; Christopher M. Holman, Learningfrom
Litigation: What can Lawsuits Teach us About the Role of Human Gene Patents in Research
and Innovation?, 18 KAN. J.L. & PUB. POL'Y 215 (2009); Lauren M. Dunne, "Come, Let us
Return to Reason ": Association of Molecular Pathology v. USPTO, 20 DEPAUL J. ART, TECH. &

INTELL. PROP. L. 473 (2010); Jennifer Giordano-Coltart et al., No Legal Monopoly for Genes:
Court Rules Genes are Unpatentable Subject Matter, 22 INTELL. PROP. & TECH. L.J. 8 (2010);

Debra Greenfield, Intangible or Embodied Information: the Non-Statutory Nature of Human
Genetic Material,25 SANTA CLARA COMPUTER & HIGH TECH. L.J. 467 (2009).

489. Technology Transfer News, AUTM, http://autm.net/News.htm (last visited Sept. 24,
2011).
490. See supraPart III.B.
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of the BRCA Lawsuit likely knew that their own institutions' employees
were named plaintiffs in the BRCA Lawsuit, and that these employees
(some of whom were inventors on isolated-sequence-related patents)
had alleged facts showing that isolated sequences were products of
nature and, hence, not patentable subject matter.
Thus, to the extent that the TLOs knew of the information, knew of
its materiality, and deliberately withheld that information from the
USPTO, the isolated-sequence-related patents for their respective
academic institutions are susceptible to the taint of inequitable conduct.
VII. CONCLUDING REMARKS

It is fitting that a liar should be a man ofgood memory.49 1
The lesson is simple: those who are patentees on isolated-sequencerelated patents should not argue for the invalidity of another's isolatedsequence-related patents.
First, with reference to the UPenn, Columbia, NYU, Yale, and
Emory employees who are named as inventors on isolated-sequencerelated patents, it is difficult to argue that isolated sequences are not
patentable subject matter when the university employees themselves
have patents that are directed to isolated sequences. Equally so, it is
difficult to argue for the validity of their own isolated-sequence-related
patents when the university employees are arguing for the isolatedsequence-related patents of others to be held invalid. By taking such
seemingly contradictory positions, the university employees place the
isolated-sequence-related patents of their respective institutions in
jeopardy.
Second, the institutions themselves should proceed cautiously and be
cognizant of the positions taken by their esteemed researchers. By
allowing their own researchers to make bold statements about how
isolated sequences are products of nature and, hence, not patentable
subject matter, UPenn, Columbia, NYU, Yale, and Emory may find
themselves in a precarious position of either disavowing the statements
of their own researchers, or trying to reconcile seemingly contradictory
statements.
Although Therasense ma~ have heightened the requirements for
proving inequitable conduct,4 the contradictory swom statements filed
in the BRCA Lawsuit may be sufficient to meet those heightened
requirements. 493 As previously noted, the consequences of inequitable
491. Marcus Fabian Quintilian.
492. See supra Part IV.
493. See supra Parts V & VI.
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conduct are so severe 4 94 that it may behoove those that are responsible
for prosecuting isolated-sequence-related patents to err on the side of
caution and disclose all known information to the USPTO.
Lastly, we reiterate the universal lesson that we remember from
childhood: those who live in glass houses should not throw stones.

494. See supra Part IV.
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